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RESUMO 
O cancro da bexiga (CB) é considerado o segundo tumor genitourinário mais 
comum. Divide-se clinicopatologicamente em carcinoma urotelial da bexiga não 
invasor - CUBNI - menos severo e com uma baixa taxa de mortalidade e 
carcinoma urotelial da bexiga invasor e metastático – CUBIM - um tumor de alto 
grau associado a uma elevada taxa de mortalidade. Apesar de estabelecidas 
guidelines de tratamento, a mesma abordagem para tumores com o mesmo tipo 
histológico, nem sempre dá origem aos resultados esperados. Claramente são 
necessários biomarcadores objetivos que complementem a avaliação 
clinicopatológica convencional na previsão do prognóstico, resposta à terapêutica 
e na sobrevivência dos doentes com CUBNI e CUBIM. 
O Sialil-Tn (STn) é um O-glicano resultante de uma paragem prematura no 
processo de glicosilação de proteínas extracelulares. A sua expressão influencia o 
reconhecimento por parte do sistema imunitário, afeta processos biológicos tais 
como o ciclo celular, apoptose, dinâmica do citoesqueleto, diminui a agregação 
célula-célula e aumenta a adesão extra-celular, migração, invasão e metastização 
tumoral. A expressão do antigénio STn tem sido descrita em diversos carcinomas 
humanos e em lesões preneoplásicas. Apesar desta ligação tumoral, poucos 
estudos têm sido publicados com o STn no CB. 
O principal objetivo desta tese é melhorar a estratificação dos doentes com CUB, 
tendo em conta o prognóstico, através do estudo da expressão do antigénio STn. 
Para concretizar este objetivo, o STn é estudado em três vertentes: em relação 
aos aspetos biológicos do tumor, ao seu tratamento e aos aspetos clínicos da 
doença.  
O primeiro estudo realizou-se em 69 CUB (50 CUBNI e 19 CUBI). Os resultados 
mostraram que STn não estava presente no urotélio histologicamente normal e a 
sua expressão era mais baixa nos CUBNI de baixo grau (21% tumores STn+) em 
comparação com os tumores de alto grau (67% tumores STn+), que incluem 
tumores papilares (76% tumores STn+), CIS (20% tumores STn+), e CUBI (74% 
tumores STn+). Em suma, estes resultados salientam uma associação entre a 
expressão do antigénio STn e os CUBNI de alto grau (p<0,002) e também com os 
tumores músculo-invasores (p<0,03). Observou-se ainda, usando um modelo 
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celular, que a sobreexpressão do STn aumenta a capacidade invasora das 
células tumorais. 
Avaliou-se, ainda, a influência da expressão do STn na resposta à imunoterapia 
adjuvante com Bacillus Calmette-Guérin (BCG) em doentes com tumores com alto 
risco de progressão para invasão. O trabalho foi realizado numa série de 94 
CUBNI (38 baixo grau, and 56 alto grau) que foram tratados com resseção 
transuretral seguido de imunoterapia intravesical com BCG. Aproximadamente, 
66% dos tumores estudados apresentaram positividade para o STn. A expressão 
isolada do STn ou em combinação com o S6T (STn/S6T) associou-se com os 
tumores de alto grau (p=0,007; p=0,037; respetivamente), com baixas taxas de 
recorrência após o tratamento com BCG, e apresentavam maior sobrevivência 
livre de doença. Mais, as recorrências após o tratamento mostravam uma 
expressão reduzida do STn, sugerindo que o BCG pode ser mais eficaz nas 
células que expressam este antigénio. Dados in vitro confirmaram que a 
expressão de STn aumentava a adesão do BCG às células de bexiga e, 
consequentemente, a morte celular. 
No terceiro estudo foram avaliados 96 tumores – 47 CUBNI e 49 CUBI; 16 de 
baixo grau e 80 de alto grau. A expressão do STn foi estatisticamente associada 
com o estádio histológico ≥T1-T4 (p<0,001), e com uma pior sobrevivência 
específica após o tratamento do tumor (p=0,024). Na mesma série, foram também 
avaliadas as expressões dos marcadores envolvidos na cascata do 
phosphatidylinositol-3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR). 
Os resultados mostraram que a ativação das proteínas da via do mTOR não era 
discriminatória em relação ao estádio histológico nem permitia a identificação dos 
doentes com pior prognóstico. Nos tumors invasores, os que expressavem STn e 
tinham a via do mTOR ativa (pAkt+ e/ou pmTOR+ e/ou pS6+), mostraram uma 
sobrevivência específica significativamente menor (p=0,027). Neste estudo a 
expressão do STn também foi avaliado numa série de ratinhos ICR submetidos ao 
agente carcinogénico N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) para 
desenvolverem carcinoma da bexiga. Descreve-se, pela primeira vez que tumores 
da bexiga quimicamente induzidos expressam STn, mimetizando o padrão de 
glicosilação em carcinomas humanos. Foi observado o efeito do sirolimus (um 
análogo da rapamicina) nos tumores. A administração do sirolimus foi eficaz nas 
células tumorais STn positivas.  
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Nesta tese, conseguiu compreender-se melhor o significado da expressão do 
antigénio STn no contexto dos tumores de bexiga. Demonstrou-se claramente que 
o STn está associado a este carcinoma, nomeadamente a tumores avançados, 
altamente proliferativos, à invasão e disseminação da doença, e a uma diminuição 
significativa da sobrevivência livre de doença. Também se concluiu que a 
presença de STn interfere de forma positiva na resposta à terapêutica destes 
tumores. Estas descobertas fazem do antigénio Sialil-Tn um marcador de 
prognóstico a ter em conta e sugerem a sua utilização em terapêutica guiada para 
cancro da bexiga. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
ABSTRACT 
Bladder cancer (BC) is the second most common genitourinary malignancy. It 
ranges from mild disease with a low mortality rate (classified as NMIBC - non 
muscle invasive bladder cancer) to extremely high-grade tumours associated with 
high mortality (classified as MIMBC - muscle invasive or metastatic disease). 
Although treatment guidelines are already defined, the same treatment for the 
same histological type, several times results in different outcomes. Clearly, 
objective biomarkers are needed in clinics to complement conventional 
clinicopathological evaluation to predict prognosis, treatment response and 
survival in both NMIBC and MIMBC patients. 
Syalil-Tn (STn) is an O-glycan resulting of a premature stop in the glycosylation 
process of the extracellular proteins. Its expression influences cell recognition by 
the immune system, affecting processes as cell cycle, apoptosis, and actin 
cytoskeleton dynamics, decrease cell-cell aggregation and increase extra-cellular 
adhesion, migration, invasion and cancer metastization. Overexpression of STn 
antigen has been detected in several human carcinomas and preneoplastic 
lesions. Despite the cancer-associated nature of the STn antigen, few studies 
have been presented for BC. 
The main objective of this thesis is to improve BC patient’s stratification using STn 
expression. In order to accomplish it, STn is studied in three dimensions: relating it 
with tumour biology, with the tumour treatment and with the clinical outcome. 
The first study used 69 urothelial BC patients (50 NMIBC and 19 MIBC). The 
results showed that STn was not expressed in the normal urothelium and its 
expression was lower in low-grade (LG) NMIBC (21% STn+ tumours) compared to 
high-grade lesions (HG; 67%), which include papillary tumours (76% STn+ 
tumours), CIS (20% of STn+ tumours), and MIBC (74% STn+ tumours). 
Altogether, these results highlight an association between the STn antigen and 
high grade NMIBC (p<0.002) as well as with muscle invasive tumours (p<0.03).  
Using a cell line model, it was observed that the STn overexpression increases the 
invasive capacity of BC cells.  
It was evaluated the STn expression role in the response to adjuvante 
immunotherapy with BCG (Bacillus Calmette-Guérin) in patients with high risk 
BC.The study was performed in a series of 94 (38 LG, and 56 HG) NMIBC treated 
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with transurethral resection followed by for BCG intravesical immunotherapy. 
Approximately 66% of the studied BC were STn positive. STn expression alone or 
in combination with S6T (STn/S6T) was associated with high-grade tumours 
(p=0.007; p=0.037, respectively), being also associated with lower recurrence 
rates after BCG, and presented longer recurrence free survival (RFS). Moreover, 
recurrences after treatment displayed a reduced expression of STn antigens 
suggesting that BCG may be more effective against cells expressing these 
glycans. In vitro data confirmed that STn expression increased BCG adhesion to 
bladder cells, and consequently cell death.  
In the third study 96 tumours were evaluated – 47 NMIBC and 49 MIBC; 16 as LG 
and 80 as HG. STn expression was statistically associated with histological stage 
≥T1-T4 (p<0.001), and with worst cancer specific survival (CSS; p=0.024). In the 
same series, the expression of phosphatidylinositol-3-kinase (PI3K)/Akt/ 
mammalian target of rapamycin (mTOR) pathway markers was also addressed. In 
the studied series the results showed that the activation of mTOR pathway 
proteins did not discriminate the stage of disease and did not allow the 
identification of patients facing worst prognosis. In advanced stage STn 
expressing tumours with an active mTOR cascade (positive pAkt and/or pmTOR 
and/or pS6) showed a significantly worst CSS (p=0.027).  
STn expression was also evaluated in a series of ICR mice that were submitted to 
the carcinogenic agent N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) to develop 
BC. For the first time, it is described that chemically-induced bladder tumours 
express the STn antigen, also mimicking the glycosylation pattern of human 
tumours. The effect of sirolimus in the tumours of the same mice was observed. 
The administration of sirolimus was effective against STn and pS6 positive cells.  
In this work, a more comprehensive description of STn antigen expression in BC 
was achieved. It was clearly demonstrated that STn is associated with this cancer, 
and advanced and highly proliferative tumours, invasion and organ disseminated 
disease, and with a significant decrease in cancer specific survival. It also 
interferes positively with the response to treatment. All of these findings engender 
STn a prognostic marker for BC and suggest its usefulness in guided therapy for 
this cancer. 
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1.1. Bladder Cancer 
 
Bladder cancer (BC) is the second most common genitourinary malignancy [1]. It 
is the fourth most prevalent disease in the United States accounting for 7 percent 
of cancers in men [2]. Bladder cancer ranges from mild disease with a low 
mortality rate to extremely high-grade tumours associated with high mortality [3].  
Accurate staging and grading is important to select optimal treatment. Bladder 
cancer has a clear correlation with environmental exposures, such as smoking [3]. 
High recurrence rates, long-term follow-up, and the frequent need for repeated 
interventions are the major causes that turn BC the costliest to treat among all 
solid tumours [3,4,5]. Therefore, accurate staging and grading are essential to the 
refinement of the prognosis and better allocation of treatment resources. 
 
Epidemiology 
An estimated 386,300 new cases and 150,200 deaths from BC occurred in 2008 
worldwide. The majority of BC occurs in males and there is a 14-fold variation in 
incidence internationally. The highest incidence rates are found in the countries of 
Europe, North America, and Northern Africa. Egyptian males have the highest 
mortality rates (16.3 per 100,000), which is twice as high as the highest rates in 
Europe (8.3 in Spain and 8.0 in Poland) and over 4 times higher than that in the 
United States (3.7). The lowest rates are found in the countries of Melanesia and 
Middle Africa [6].  
Bladder cancer is the 7th most common cancer in men and the 17th most common 
in women worldwide. BC is more common in developed countries being the 4th 
and 9th most common cancer in men and women, respectively, in the Western 
world [6]. In the United States, in 2007, approximately 50,000 men and 17,000 
women were diagnosed with BC, and near 14,000 succumbed by this disease [1]. 
About 74,690 new cases were expected for 2014, being 56,390 in men, with an 
estimated death of 11,170 men from this cancer [2]. BC is primarily found in elder 
persons, with approximately 80 percent of new cases occurring around 60 years or 
older [7]. BC is about three times more common in men (one in 27) than women 
1. Introduction 
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(one in 85). It is more prevalent in white persons; however, because of delayed 
diagnosis, mortality rates are higher in black persons [8]. 
According to the Registos Oncológicos Regionais, in Portugal, in 2006 were 
diagnosed 1711 new BC, 1336 of which affecting men and 375 affecting women. 
In the same year, 514 men and 186 women died from this malignancy turning BC 
the 7th most prevalent type of tumor and the 8th most common cause of death 
from cancer [9].  
Risk factors 
Well established risk factors for bladder cancer include tobacco use, infections 
with Schistosoma haematobium, and occupational exposures to aromatic amines 
and polycyclic aromatic hydrocarbons [10,11]. Other suspected risk factors for BC 
include dietary patterns, environmental pollution, and genetic predisposition [11]. 
Age is also considered a bladder cancer risk factor because it occurs 
predominantly in the elder [3]. 
Incidence and mortality rates vary globally, mainly due to differences in risk 
factors. While smoking is the predominant cause of bladder cancer in the United 
States, infection with S. haematobium is the major cause of the disease in most 
parts of Africa [12]. 
According to Burger et al. (2013) the understanding of genetic risks in BC is 
growing steadily [11]. The risk for this malignancy is two-fold higher in first-degree 
relatives of BC patients. Inherited genetic factors, such as the genetic slow 
acetylator N-acetyltransferase 2 (NAT2) variants and glutathione S-transferase mu 
1 (GSTM1)–null genotypes, have been established as risk factors for BC. Factors 
such as slow acetylation may not intrinsically lead to BC but may confer additional 
risk to exposure of carcinogens such as tobacco products [11]. 
Smoking is the most important risk factor for BC, having a direct pathophysiologic 
link between them [11]. Smokers are at least 3 times as likely to develop BC as 
nonsmokers. Smoking causes about half of the BC in both men and women [13]. 
Tobacco smoke contains aromatic amines, such as b-naphthylamine, and 
polycyclic aromatic hydrocarbons known to cause BC. Moreover, these 
compounds are renally excreted and exert a carcinogenic effect on the entire 
urinary system. Tobacco consumption is common, and thus its epidemiologic 
impact is massive [11]. 
1. Introduction 
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Following smoking, occupational exposure to carcinogens is viewed as the second 
most relevant risk factor for BC [11,14]. In industrialized countries, 5 to 10 percent 
of diagnosed BC are caused by occupational exposures to aromatic amines 
(benzidine, 4-aminobiphenyl, 2-naphthylamine, 4-chloro-o-toluidine) used in the 
manufacturing of chemical dyes, pharmaceuticals and in gas treatment plants 
[11,14]. Some studies show that sometimes the disease appears only 30 to 50 
years after exposure [3]. 
Bladder exposure to radiation, often as treatment for other pelvic malignancies, as 
well as cyclophosfamide and other similar chemotherapeutic agents, has been 
linked to secondary BC, which may be particularly aggressive. These cancers tend 
to be high grade and locally advanced [15,16]. 
 
Clinical presentation 
 
Painless visible hematuria is the most common presenting symptom in patients 
diagnosed with BC [16,17]. However, symptoms of bladder irritation, such as 
urinary frequency and urgency, more commonly occur in patients with bladder 
carcinoma in situ (CIS). Obstructive symptoms may be present if the tumour is 
located near the urethra or bladder neck. In advanced disease, patients may 
present flank pain caused by uretheral obstruction, or with abdominal, pelvic, or 
bone pain from distant metastasis. Early bladder cancer is not detectable by 
physical examination, however, a palpable kidney or pelvic mass may be present 
in advanced and metastatic disease (Table 1) [17,18]. 
 
 
Table 1. Signs and Symptoms of Bladder Cancer (adapted from [3]) 
Hematuria (gross or microscopic) 
Irritative symptoms 
     Dysuria, frequency, urge incontinence, urgency 
Obstructive symptoms 
     Decreased force of stream, feeling of incomplete voiding, intermittent stream, straining 
Signs and symptoms of metastases or advanced disease 
     Abdominal, bone, flank, or pelvic pain; anorexia, cachexia, or pallor; lower extremity edema; 
renal failure; respiratory symptoms (e.g., cough, dyspnea, hemoptysis); suprapubic palpable 
mass 
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Fifty to seventy percent of NMIBC tend to recur within 5 years after surgical 
excision, rarely progressing to invasive cancer (10-30%). The vast majority of 
MIBC occur in patients without a prior history of papillary tumours and have a poor 
prognosis [3,21]. 
In 1998, a new histological grading classification of non-invasive urothelial tumours 
was proposed by the World Health Organization (WHO) and the International 
Society of Urological Pathology (ISUP) (1998 WHO/ISUP classification) and 
published by the WHO in 2004 [22]. According to this new classification, grade 1 
tumors are reclassified has papillary urothelial neoplasms of low malignant 
potential (PUNLMP). Although these lesions do not have cytological features of 
malignancy, they show normal urothelial cells in a papillary configuration. In spite 
of PUNLMP have a negligible risk for progression, they are not completely benign 
and still have a tendency to recur. In addition, the intermediate grade (Grade 2) 
has been eliminated in this new classification (Figure 1; Table 2). 
 
 
Table 2: WHO grading in 1973 and in 2004 (adapted from [22]) 
1973 WHO grading  
Urothelial papiloma 
Grade 1: well differentiated 
Grade 2: moderately differentiated 
Grade 3: poorly differentiated 
2004 WHO grading 
Urothelial papilloma (completely benign lesion) 
Papillary urothelial neoplasm of low malignant potential (PUNLMP) 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
 
 
 
Based on available prognostic factors and particularly data from the European 
Organization for Research and Treatment of Cancer (EORTC) risk tables, the 
Guidelines Panel recommends stratification of patients with non-muscle invasive 
bladder cancer into three risk groups, such as low-risk, intermediate-risk and high-
risk (Table 3). This group stratification enables the prediction of the risk of 
 recurrence and progress
tumour [22]. 
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Diagnosis 
 
Clinical investigation should begin with the careful knowledge of patient’s 
background, including any associated risk factors. Patients with urinary symptoms 
should have a urinalysis with urine microscopy and a urine culture to rule out 
infection [24]. 
 
The primary means of BC diagnosis and surveillance are the cystoscopic 
examination of the bladder, as well as the cytologic examination of the cellular 
material present in the urine [24].  
Urine cytology has a high specificity (95 to 100 percent), but a low sensitivity (66 to 
79 percent) for the detection of BC. Urine cytology is frequently used to identify 
high-grade tumours and monitor patients for persistent or recurrent disease 
following treatment. Moreover, bladder wash cytology detects in situ carcinoma in 
almost all cases [16]. However, it fails to detect BC in asymptomatic patients [16].  
 
A number of noninvasive tests to detect BC have been developed and approved 
for clinical practice by the Food and Drug Administration agency (FDA), namely, 
BTA STAT, BTA TRAK, NMP-22, ImmunoCyt/uCytt and UroVysion [25]. It is 
interesting to note that almost all tumour markers have a much better sensitivity 
than cytology but few reached the same level of specificity. Nevertheless, 
cystoscopy remains the mainstay of diagnosis and surveillance, providing 
information about the tumour location, appearance, and size. Detection of flat 
neoplastic lesions, such as in situ carcinoma, can be improved by using 
fluorescence cystoscopy [16].  
Other means of diagnosis include bladder biopsies, computerized tomography or 
magnetic resonance imaging scans, which is particularly useful to evaluate the 
presence of bladder wall thickening, perivesical fat invasion, and lymph node 
involvement [23]. In turn, transurethral resection of the tumour (TURBT) is 
indicated when the tumour is localized and cytologies are suggestive of 
malignancy [15]. 
 
 
1. Introduction 
22 
 
 
Treatment 
 
Optimal treatment involves a multidisciplinary approach, combining the urology, 
pathology, and oncology fields. After the diagnosis, several treatments can be 
implemented according with the grade and stage of the tumour. Moreover, a close 
follow-up is essential for BC patients [16]. 
 
  -  Nonmuscle invasive bladder cancer 
TURBT is one of the most common procedures used by practicing urologists for 
the diagnosis, staging and treatment of NMIBC [26].  
The standard treatment of Ta and T1 BC is complete endoscopic resection, with or 
without adjuvant intravesical therapy [15]. Concomitant intravesical therapy 
depends on the depth and grade of tumour invasion, completeness of resection, 
and estimated probability of recurrence. For instance, low-grade Ta tumors are 
treated with resection alone [16]. Bacillus Calmette-Guérin (BCG), an attenuated 
strain of Mycobacterium bovis, is the most commonly used form of intravesical 
immunotherapy. BCG is currently used for CIS and recurrent nonmuscle invasive 
disease [15]. The response to intravesical treatment with BCG or chemotherapy is 
an important prognostic factor for subsequent progression and death caused by 
BC. Approximately 10-20% of complete responders eventually progress to muscle-
invasive disease, compared with 66% of non-responders [22]. 
Mitomycin C, epirubicin, and doxorubicin are also used as adjuvant therapy and 
have all shown a beneficial effect, with no efficacy comparisons made between the 
drugs [22]. Although BCG therapy causes significantly more side effects than 
chemotherapy, it appears to be significantly better at preventing recurrences than 
regimens based on mitomycin C (MMC) or epirubicin [22]. 
    
 - Muscle invasive bladder cancer 
Radical cystectomy with pelvic lymphadenectomy is the standard treatment for 
MIBC (stage ≥T2) [16,23]. However, only 50% of patients exceed the 5-year 
survival mark when submitted to this procedure. The use of peri-operative 
chemotherapy has been explored since the 1980s. There are many advantages of 
administering chemotherapy before surgery or radiation therapy, such as reduction 
1. Introduction 
23 
 
of tumor size and possible reduction of micrometastatic disease [23]. According to 
BC guidelines 2013, neoadjuvant cisplatinum-based combination therapy is 
recommended for T2-T4a, and cN0M0 BC [23]. The combination therapy based on 
gemcitabine (Gemzar) and cisplatin (Platinol) is the standard adjuvant treatment 
for most patients because of its lower toxicity, when compared to other 
combinations, such as the MVAC regimen (methotrexate, vinblastine, doxorubicin 
– Adriamycin – and cisplatin) [16]. Table 4 resumes the standard treatments of 
urothelial bladder carcinoma according to its clinical features.  
 
Table 4. Treatment of Urothelial Bladder Carcinoma (Adapted from [16]) 
 
    Tumour                                 Treatment 
Low-grade Ta            Transurethral resection without intravesical chemotherapy  
                                   Some experts suggest a single dose of intravesical chemotherapy  
                                   (not immunotherapy) within 24 hours of resection to prevent recurrence 
                                
 
High-grade Ta            Repeat transurethral resection (if lymphovascular invasion, incomplete resection, 
                                   or no muscle in the specimen), consider intravesical BCG (preferred) or  
                                   mitomycin 
 
Carcinoma in situ/      Transurethral resection followed by intravesical BCG once a week for six weeks 
tumour in situ                   
 
Low-grade T1             Repeat transurethral resection followed by intravesical BCG (preferred) or  
                                   mitomycin                                       
                                    
High-grade T1            Repeat transurethral resection, followed by intravesical BCG or mitomycin, or  
                                   cystectomy                                        
 
T2a or T2b (organ      Radical cystectomy followed by chemotherapy in high-risk patients (e.g., those 
confined)                     with nodal involvement, highgrade histology, transmural or vascular invasion,  
                                    pathologic T3 lesion)                                       
 
T3a or T3b                  Radical cystectomy followed by adjuvant chemotherapy, consider neoadjuvant 
                                    Chemotherapy 
                                    Two trials have shown survival benefit with neoadjuvant chemotherapy (three  
                                    cycles of methotrexate, vinblastine, doxorubicin [Adriamycin], and cisplatin  
                                    [Platinol]) in T2 or T3 disease 
 
T4a, T4b, or                Chemotherapy alone or in combination with radiation therapy, except in high-risk 
metastatic disease      patients (e.g., those with poor performance status, visceral [lung or liver]  
                                    disease, bone disease, poor cardiac status)                                
                                    Radiation therapy not routinely used in the United States for locally advanced      
                                    bladder cancer 
  
BCG = bacille Calmette-Guérin. 
 
 
As previously described, muscle invasive bladder cancer is amongst the most 
common and deadliest genitourinary cancers. The mainstay treatment is cisplatin-
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based regimens, which fail in avoiding tumour relapse and disease dissemination, 
urging novel biomarkers for accurate patient stratification and new therapeutics. 
 
 
1.2. Glycosylation and Sialyl-Tn 
 
Protein O-glycosylation in eukaryotic cells 
  
Complex carbohydrates are the major components of the cell membrane, having 
important biological implications in cell-cell or cell-extracelular matrix interactions, 
as well as signal transduction. There is a distinct difference in carbohydrate 
profiles between normal and tumour tissues. Aberrant glycosilation is responsible 
for the characteristic carbohydrate expression associated with malignant 
transformation, being catalysed by specific glycosyltransferases and glycosidases 
[27]. Glycosylation is the most common post-translational modification in proteins 
and plays a pivotal role in structural and functional features of several molecules – 
in fact, virtually, all proteins can be glycosylated [28,29]. It mainly affects the outer 
part of the carbohydrate moiety of glycoproteins and glycolipids, leading to the 
expression of tumour-associated carbohydrate antigens (TACAs). Many TACAs 
are sialylated structures and the general increase in cell surface glycoproteins 
sialylation is commonly observed in N-linked and O-linked oligosaccharides of 
carcinoma cells [30]. Altered or aberrant glycosylation is common in several 
human carcinomas, especially during tumour progression, modifying cellular 
adhesion and motility, affecting their invasive and metastatic potential [31].  
Protein O-glycosylation is a stepwise pathway that begins in the Golgi apparatus 
of eukaryotic cells, in which monosaccharides are added individually and 
sequentially to an hydroxyl oxygen in Serine/Threonine (Ser/Thr) tandem repeat 
regions of proteins by a complex set of enzymes (Figure 4) [29,32].  
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Key: Gal        GalNac          GlcNac           NeuAc          Fuc      
Figure 4 - Steps of mucin-type O-glycan biosynthesis. O-glycosylation occurs post-translationally 
by covalently α-linking a GalNAc moiety from a sugar donor UDP-GalNAc to protein serine (S) or 
threonine (T) residues by UDPGalNAc-polypeptide N-acetylgalactosaminyl- transferases 
(ppGalNAc-Ts). After the first glycan (GalNAc) is added, forming the Tn antigen, the core 1 
structure is synthesised by the Gal-transferase (β(1-3)-galactosyltransferase, C1Gal-T1 or T-
synthase), which adds Gal to GalNAc. Core 1 may function as a precursor of other core structures 
(from core 2 to 8), by the addition of different monosaccharides, such as galactose, fucose, N-
acetylgalactosamine, N-acetylglucosamine and sialic acids. Adapted from [45]. 
 
1. Introduction 
26 
 
 
O-glycans are highly expressed in mucins, a class of heavily glycosylated proteins 
secreted by mucosa and some exocrine glands [28,33]. These high molecular 
weight proteins are rich in Ser and Thr residues, providing the necessary template 
for O-glycosylation [28,33-35]. As a result of its association with mucins, cell 
surface O-glycans are commonly designated as mucin-type O-glycans; 
nevertheless, O-glycans can also be found in many other cell glycoproteins 
exhibiting Ser and Thr residues [28]. Nuclear O-glycosylation can also occur in the 
cells and it is a process in which a certain variation of O-glycosylation is seen in 
the nucleus and cytosol. This O-glycosylation is characterized by a single N-
acetylglucosamine (GlcNAc) attachment to Ser/Thr residues, and appears to have 
a signaling role similar to protein phosphorylation [36,37]. Mucin-type O-glycans 
synthesis begins with the transfer of an α-N-acetylgalactosamine (GalNAc) from 
the donor-nucleotide sugar uridine diphosphate – N-acetylgalactosamine (UDP-
GalNAc) to the hydroxyl group of a residue of Ser/Thr within the glycoprotein being 
synthesized [28,29,38]. This reaction forms the simplest mucin O-glycan and the 
only structure common to all O-glycans – the Tn antigen (GalNAcα-O-Ser/Thr) 
[35]. This antigen can be sialylated at the O-6 position, generating the sialyl-Tn 
(STn, Neu5Acα2-6GalNAcα-O-Ser/Thr) antigen, by the action of the ST6GalNAc-I 
sialyltransferase. The sialylation of this O-glycan stops further chain elongation 
(Figure 5) [28,39,40]. Alternatively, the Tn antigen can give raise to other core 
structures [35].  
Carbohydrate structures formed by a GalNAc or by a Galβ1-3GalNac disaccharide 
O-linked to Ser/Thr, as well as their sialylated forms are collectively denominated 
as Thomsen-Friedenreich-related antigens (TF-antigens) (Figure 5). As previously 
described, their biosynthesis depends on a coordinated action of several 
glycosyltransferases [40].  
The initial step of O-glycosylation is catalyzed by a family of 20 membrane-bound 
enzymes denominated UDP-GalNAc:polypeptide glycosyltransferases (ppGalNAc-
Ts), that have distinct but overlapping specificities [29,32]. This family of enzymes 
has a C-terminal lectin domain, which makes them unique among all others 
eukaryotic glycosyltransferases [36,41]. This diversity, as well as the fact that O-
glycosylation sequence consensus motif has not emerged yet, allows a fine tuned 
 control of the initiation of
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aggregation and proteosomal degradation of T-synthase, and is required for the 
export of the enzyme from the ER, leading to the formation of core 1 [43,44].  
T antigen can be sialylated at O-3 position by a ST3Gal-sialyltransferase, yielding 
the sialyl-3-T antigen (S3T, Neu5Acα2-3Galβ1-3GalNAcα-O-Ser/Thr); this antigen 
can be further sialylated at O-6 position, by a ST6Gal-sialyltransferase, originating 
the di-sialyl-T antigen (diST, Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-O-
Ser/Thr) (Figure 5) [28,40]. Alternatively, the GalNAc residue of the T antigen may 
be sialylated at the O-6 position by a ST6GalNAc-sialyltransferase, yielding the 
sialyl-6-T antigen (S6T, Galβ1-3(Neu5Acα2-6) GalNAcα-O-Ser/Thr), which can 
then originate the diST antigen (Figure 5). Tn and T antigens, as well as their 
sialylated structures that block further elongation of the O-chain, are generally 
designated simple mucin-type O-glycans [33,35].  
Core 1 functions as a precursor of other core structures (from core 2 to 8), by the 
addition of different monosaccharides, such as galactose, N-acetylgalactosamine, 
N-acetylglucosamine and sialic acids [32,36].  
Core 2 is synthesized in many epithelial (as intestinal mucosa) and hematopoietic 
tissues by the addition of a branching GlcNAcβ(1-6)-linked residue to core 1, by 
core 2 β(1-6) N-acetylglucosaminyltransferases (or C2Gn-T) (Figure 5) [28,40,45].  
Alternatively to core 1 O-glycan formation, GlcNAc instead of Gal can be 
transferred in a β1–3 linkage by a core 3 β(1-3) N-acetylglucosaminetransferase 
(C3Gn-T3) to Tn antigen forming the core 3 structure,  as represented in Figure 5, 
and the subsequent addition of a GlcNAc residue onto core 3 by a C2Gn-T yields 
core 4. Thus, the prior synthesis of core 3 is required for the formation of core 4 
[32,40,45].  
The extension of core units provides a vast array of glycan structures, and is 
catalyzed by N-β3/4-acetylglucosaminyltransferases (β3/4 Gn-Ts) and/or β3/4-
galactosyltransferases (β3/4 Gal-Ts), leading to the formation of side chains 
designated type-1 (Galβ1-3GlcNAc-R) and type-2 (Galβ1-4GlcNAc-R) chains 
[28,32,36]. These chains present a ubiquitous expression, and therefore are 
widely expressed among epithelial tissues. Type-1 and type-2 chains can be 
modified by the action of fucosyl and sialyltransferases, yielding ABO blood group 
determinants and/or Lewis blood group related antigens (Lea, SLea, Lex, SLex, 
Leb and Ley), which function as terminal structures by stopping chain elongation 
[28,32,36]. After O-glycosylation is concluded, the formed structures can undergo 
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modifications, such as phosphorylation, sulfation and methylation, which constitute 
an additional mean for their diversity [36].  
O-GalNAc glycans are crucial structures for cells viability, because they play 
several and distinct roles in the organism, depending on the structure on which are 
present – this structural variability allows them to function as signaling, recognition 
and adhesion molecules [33,38,46]. 
 
Regulation of O-glycosylation  
 
As O-GalNAc glycans are complex and widely diverse structures, their synthesis is 
tightly regulated. However, the exact mechanisms by which this regulation occurs 
remains to be clarified [33,34]. The regulation of O-glycosylation seems to be 
dependent on the pattern of the enzymes involved in this process – substrate 
specificity, intracellular localization and level of relative activity are the main control 
factors of O-glycosylation [33,34,37].  
Substrate specificity of glycosyltransferases and other enzymes involved in O-
glycosylation restricts the number of possible O-GalNAc glycans that can be 
formed, since these enzymes act in well-defined substrates [33,41]. On the other 
hand, this specificity reduces the number of pathways by which O-glycans can be 
synthesized [33,41]. For example, ST antigen can only be generated by the 
addition of a sialic acid residue to T antigen (core 1). The adding of a galactose 
residue to STn antigen does not yield the same structure, that if added to Tn, since 
the sialic acid present in STn antigen blocks the action of other 
glycosyltransferases, namely C1Gal-T1 [33,40].  
Intracellular localization of glycosyltransferases is another important regulation 
factor of O-glycosylation, which is determined by the physical separation of 
enzymes within the Golgi compartments [41,35]. These enzymes appear to be 
arranged in an assembly line in the Golgi apparatus – early acting 
glycosyltransferases occupy the cis-Golgi, intermediate acting enzymes are 
localized in the medial Golgi and terminal acting enzymes in the trans-Golgi, which 
allows a tight control of O-glycosylation [33,35].  
The third major control factor is the level of enzymatic activity of 
glycosyltransferases, that consequently dictate the relative amounts of 
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synthesized O-glycans. For instance, the activity of two competitive enzymes will 
determine the nature of the O-GalNAc glycan being synthesized, depending on 
which activity predominates [41,46]. Besides the competition between 
glycosyltransferases, other regulatory components influence glycosyltransferases 
activation, namely specific binding proteins such as the Cosmc chaperone [33,43]. 
 
Alterations of O-glycosylation in cancer  
 
Aberrant glycosylation is considered a hallmark of malignant transformation, and 
has been observed for almost 20 years [28,31,33,34]. In particular, O-glycans play 
important roles in the attachment and invasion of cancer cells, as well as in their 
survival in the blood stream [35]. Tumour-associated glycans can be found in the 
surface of cancer cells, and therefore are easily accessible to antibodies and 
lectins [47,48]. Moreover, they are released to the peripheral circulation, either in 
secreted glycoproteins or by shedding from cell surfaces – these features allow 
them to be explored in various serological assays [33,47]. As such, the presence 
of tumour-associated glycans in serum is used for post-surgical follow-up, to 
determine disease recurrence, progression and response to therapeutics [49].  
Among the most common structural features associated with cancer are the 
altered expression of terminal structures, which includes loss of ABO(H) 
determinants by secretor individuals and changes of Lewis antigenic patterns 
[33,35]. Moreover, mucins over-expression [50,51], particularly MUC1, and the 
incomplete O-glycosylation, yielding low molecular weight O-glycans, namely T 
and STn, are also associated with the malignant transformation of cells [40,33].  
The first evidences of alterations in glycosylation patterns of tumour cells concerns 
the loss of ABO(H) blood group determinants in gastric cancer [52]. Then, the 
correlation between the degree of A/B determinants deletion, invasion and 
metastatic spread was described in lung [53] and head and neck [54] carcinomas. 
Blood group antigens are known to be involved in several cellular activities, such 
as cell adhesion, cell recognition and cell-cell signaling [27].   
Lewis blood group antigens are related carbohydrates structures used as markers 
of cell differentiation. In adults, they are present in erythrocytes as well as in 
different tissues and organs. It has been shown that neoplastic transformation is 
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often associated with characteristic changes in the expression of these blood 
group oligosaccharides, and their amounts usually increase during tumour 
progression and acquiring of malignant phenotype [55]. 
Changes in Lewis antigenic patterns are related to over-sialylation of terminal 
structures resulting in an over-expression of SLea and SLex antigens. The 
referred alterations in glycosylation stem come from an aberrant expression of the 
genes encoding sialyl and fucosyltransferases [28,30]. Since 1980s several 
studies begun to demonstrate the role of SLea and SLex expression in cancer 
specimens, using monoclonal antibodies [56].  
The presence in tumour cells of SLea or SLex, which are ligands for selectins, 
promotes the metastatic process by facilitating the interaction of cancer cells with 
the endothelium of distant organs, been demonstrated to be correlated with poor 
prognosis [40,57]. According to Takada et al. (1993) SLea antigen is mainly 
responsible for adhesion of human colon, pancreas and gastric cancer cells to the 
endothelium, whereas binding of lung, liver and ovarian cancer cells is mediated 
by SLex [58]. The loss of A and B antigens increases cellular motility, while the 
presence of O(H) epitopes increases resistance to apoptosis by mechanisms that 
remain to be defined [57]. 
Sialylated Lewis (SLe) antigens can also be released into the bloodstream by 
malignant cells – thus, soluble forms of these antigens are also expressed in high 
amounts in the blood of many cancer patients [33,34]. Studies based on the 
average survival of patients with gastric carcinomas after surgery revealed that 
high levels of SLea and SLex correlated with lower survival [59,60]. Based on 
these features, SLea and SLex are currently used in non-invasive assessment of 
tumour progression and metastatic spread [28,33,38].  
 
Normal epithelial cells derived from different organ sites express a subset of the 
more than 20 mucin core proteins, which are heavily O-glycosylated in a specific 
manner to the requirements of the epithelial cell surfaces in that organ. The 
process of transformation to malignant state results in the expression of different 
mucin core proteins with distinct patterns of complex O-linked glycosylation, 
principally in the tandem repeat domain. In cancer includes short, truncated 
structures not seen in normal epithelia. Of these shortened structures, the most 
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notable are the pan-carcinoma structures STn and Tn along with core 1 glycan 
extension, the T antigen [61]. 
Mucins have several functions like protection and lubrification, forming a selective 
barrier in epithelial surfaces. However, they can be found in more complex 
biological processes, as epithelial regeneration and differentiation, cellular 
adhesion and signaling [62-64].  
Mucins are the major epithelial luminal surface glycoproteins and are 
characterized by their high molecular masses (> 200 kDa) and content of 
carbohydrate side chains (~90%) [65].  
The over-expression of mucins during neoplastic transformation, namely MUC1 
mucin, has been widely documented [50,51,66].  
MUC1 is a transmembrane glycoprotein with a large extracellular mucin-like 
domain, formed by 30-90 repeats of 20 homologous amino acids rich in O-
glycosylation sites [67,68]. In carcinomas, MUC1 is expressed over the entire cell 
surface, in abnormally large amounts, opposing to the expression on the apical 
domain of normal epithelial cells [33,51]. Since the extracellular domain of MUC1 
is long, dense and relatively rigid, due to the abundance of O-glycan 
oligosaccharides, adhesion molecules present in cell surface, such as cadherins 
and integrins, become shielded. Thus, cell-cell and cell-extracellular matrix 
interactions decrease, creating an anti-adherent effect [51,69]. Consequently, 
MUC1 has the capability to induce detachment of a cell from the primary lesion, 
leading to invasion and metastasis. This process escapes from immune 
surveillance, because MUC1 inhibits the interaction between cytotoxic 
lymphocytes and the target cell and promotes apoptosis of lymphocytes, allowing 
the detached cell to survive in the bloodstream or in distant organs [33,69]. In 
addition, the concomitant expression of SLex or SLea facilitates the adhesion of 
tumour cells to the vascular endothelium, promoting metastasis [38,40] Over-
expression of MUC1 is generally correlated with higher aggressiveness and 
metastatic capability of the tumour [51,69].  
The sialylation of T (ST) and Tn (STn) antigens is the product of abnormal 
glycosylation, as explained above. In fact, these antigens expressed in many 
primary human carcinomas such as ovarian, esophagus, gastric, colon, head and 
neck, breast, carcinomatous mesothelium, bladder, pancreas and cervix, whereas 
very low levels or no expression are found in healthy tissues [30,39,66,70-76]. 
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Therefore, ST and STn antigens have been extensively studied in last decades 
and are widely assumed as pan-carcinoma biomarkers [39,34,77].  
T antigen is also considered a pan-carcinoma antigen, once it is substantially over-
expressed in several carcinomas, namely breast, bladder, colon, gastric and 
prostate, being associated with a worse prognosis [30,72,74,78-81]. Nevertheless, 
T antigen is also expressed in normal tissues although in low levels, because at 
some time it undergoes further glycosylation [72,78,79]. The alterations in 
glycosylation patterns during malignancy are often the result of altered activities of 
sialyltransferases in cancer cells. This is evident in the specific and preferential 
display of certain glycoconjugates, like ST or STn on cancer cells [30,38]. As 
previously described, the upregulation of sialyltransferases and consequent 
increase in the sialic acid content usually blocks further glycosyltransferase activity 
and chain elongation [35,40]. Consequently, neoplastic cells express heavily 
sialylated and truncated O-GalNAc glycans, namely ST and STn antigens, which 
have an increased ability to bind to adhesion molecules present in endothelial 
cells, such as selectins [35,39,40]. Therefore, these highly sialylated O-glycans 
have an enormous invasive potential and metastasis capability [35,39].  
The Golgi apparatus disorganization can also affect the glycan content of cells. 
For instance, in normal cells, the GlcNac-transferases responsible for initiation of 
core 1 and core 2 O-glycans are localized in the cis-Golgi, whereas in some 
cancers they have been found throughout all Golgi compartments [82]. Gill et al. 
(2010) also suggested a redistribution of ppGalNAc-Ts involved in O-glycosylation 
induced by the activation of Src kinase [42]. This activation promotes a relocation 
of the enzymes from the Golgi apparatus to the Endoplasmatic Reticulum, allowing 
them to be more time in physical contact with potential substrates. Thus, the 
occurrence of O-glycosylation is dramatically increased, resulting in an enhanced 
synthesis of truncated O-GalNAc glycans [42].  
Finally, another possible mechanism underlying the expression of cancer-
associated O-glycans, suggested by Ju et al. (2002) [83], focus on a mutation on 
the molecular chaperone Cosmc. This mutation causes loss of C1β1-3Gal-T 
activity and may contribute to expression of Tn antigen in tumor cells [83].   
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Sialyl Tn – a pan-carcinoma antigen  
 
STn detection among healthy tissues is heterogeneous [77,84]. According to Cao 
et al. (1996) the expression of this antigen was found to be positive in normal 
submandibular glands, sweat gland ducts and in gastric cells, but not in the 
esophagus, in jejuno, ilieum and gall bladder [84]; moreover, STn can be detected 
in colonic cells after the removal of O-acetyl groups [85], and it was never detected 
in normal liver (except bile ducts) and pancreas [84,85]. Focusing the urogenital 
tract, the STn antigen was found in the interstitial cells of the testis, in some 
uterine and cervix cells, but not in the ovarian neither in urinary bladder [77,84]. 
Finally, it was also detected in some cells of normal lung tissue, but not in the 
respiratory epithelium [84]. According to these authors, the expression of STn 
antigen in normal tissues is rare and/or low, when compared to cancer tissues 
[84]. Moreover, these studies evidence an expression of STn restricted to 
secreting cells, which suggest that the spread expression of this antigen in healthy 
tissues relates to external fluids of the body [77].  
As mentioned above, STn has been reported to be neo- or over-expressed in 
more than 80% of human carcinomas [30,39,70,71,75]. Therefore, STn can be 
considered a pan-carcinoma antigen and a good tumour marker of carcinogenesis 
[77]. In line with these observations, several in vitro and in vivo studies have 
associated STn antigen with aggressive cell phenotypes [30,39,77]. It has been 
demonstrated that STn expression promotes major alterations on the cell surface 
glycosylation profile, inducing or preventing the recognition by lectin like molecules 
[39]. This process contributes to a malignant phenotype, decreasing cell-cell 
aggregation and increasing extracellular membrane adhesion, migration, invasion 
and metastasis [39,77].  
In gastric cancer there is still no consensus about STn tissue immunoexpression 
prognostic value. However, according Nakagoe et al (2001) [87], pre-operative 
serum levels of STn correlate with advanced tumour stages and poor outcome, 
particularly in stage III/IV gastric cancers [87]. Other investigators, reported a 
decreased overall survival of the patients with more than 35% esophageal cancer 
STn-positive cells, when compared to the low expressing group (<35% of STn-
positive cells) [88]. Ozaki et al. (2012) described that STn-positive gastric cancer 
cells have demonstrated higher intraperitoneal metastatic ability in comparison 
1. Introduction 
35 
 
with STn-negative controls, in nude mice, resulting in increased invasion and 
decreased survival [89]. Moreover, Ogata et al. (1992) have previously 
demonstrated that mucins bearing STn antigen are effective inhibitors of natural 
killer (NK) cells cytotoxicity [90]. Thus, it was suggested that STn over-expression 
in cancer specimens induces impairment in NK cells function of the immune 
system and, subsequently, that mucins expressing the STn antigen allow cancer 
cells to escape from immune surveillance [90]. 
In fact, raised levels of serological STn have been associated with decreased 
overall survival of patients with gastric, esophagus, ovarian and colorectal cancers 
[28,77,87,91-93]. Given its biomarker value, several authors, according to their 
studies, indicate the need for STn to become a tumour marker in serological 
assays (CA 72-4) [91-93]. This antigen is present in the bloodstream due to O-
glycoprotein secretion or shedding from tumours, which occurs only when the 
tumour reaches a critical mass. Therefore, the presence of STn in serum is usually 
detected in advanced tumours, being STn considered a poor prognosis marker 
[77].  
Due to their widespread presence on the cell surface of human tumours, several 
structurally similar blood group–related carbohydrate antigens attached 
glycoproteins, in which STn is included, are promising targets for vaccine therapy.  
According to Gilewski et al. (2007), the development of a STn-based vaccine 
requires consideration of several variables. The first concerns the natural source 
of STn (from ovine submaxillary mucin or human cells) or synthetic sources that 
can influence the reactivity of monoclonal antibodies. The second one refers the 
low immunogenicity of STn because it is a carbohydrate as well as a ‘‘self-antigen’’ 
[94]. Several authors refer that one approach to increase its immunogenicity is its 
conjugation with the keyhole limpet hemocyanin (KLH) immunogenic protein 
carrier, as well as the addition of immunologic adjuvants such as QS-21 [94,95]. 
The third refers the possibility that the conformation of STn found on naturally 
occurring mucins may be different from synthetic STn [94] 
A cancer vaccine named Theratope, comprehending a synthetic STn disaccharide 
coupled to a KLH, was developed [96,97]. This cancer vaccine showed some 
promising results in animal models and phase II trials for breast and ovarian 
cancers. Briefly, these tests showed that this antigen was safe and produced a 
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strong immune response against these tumours [98,99]. Particularly, the efficacy 
of STn-carrying immunogens was investigated in a MUC1 transgenic mouse 
model. The authors reported that Theratope induced anti-STn antibodies that 
recognized this glycan in a number of glycoproteins. Moreover, a significant delay 
in tumour growth was observed in these mice, and the protection effect seemed to 
be dependent on the STn being expressed by the tumour [99]. In spite of all these 
promising preliminary results, Theratope failed phase III clinical trials for metastatic 
breast cancers, since it did not improved the endpoints of time-to-disease 
progression and overall survival rate, which was largely because it cannot induce 
strong T-cell-mediated immune response in patients [100,101]. In a recent review, 
Julien et al. (2012) discussed that the failure of Theratope was also related with 
the design of the study, namely that it disregarded the fact that only 20-30% of the 
patients with metastatic breast cancers expressed the STn antigen [77]. 
Nevertheless, the notion prevails that STn based therapeutics may constitute a 
strategy to control invasion and metastasis, and consequently improving poor 
outcomes. The fact that it is a cell-surface antigen that may be more easily 
accessible to antibodies and/or other ligands also offers potential in the context of 
guided therapeutics. 
 
1.3. Glycosylation and bladder cancer  
 
According to Ohyama (2008) glycosylation status during carcinogenesis and 
progression, invasion and metastasis in bladder cancer has been well documented 
[27].  
 
ABO Group antigens 
 
Blood group antigens have long been recognized as key molecules in cell 
recognition, adhesion, and signaling [102]. The loss of ABO blood group gene 
transcripts has been related with advanced stage bladder carcinomas [103]. These 
findings corroborate Thorpe et al. (1983) and Summers et al. (1983) which had 
also correlated the loss of ABO antigens with the invasive potential of tumours 
years before [104,105]. Moreover, Limas et al. (1985) have also associated this 
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event with high grade BC [106]. However, according to Ohno (2014) and Klatte et 
al. (2014), ABO loss might have no significance in superficial bladder tumours 
[107,108]. 
Although ABO loss was shown to be associated with advanced and metastatic 
bladder tumours, little is known about the relation between ABO type and 
prognosis of patients undergoing radical cystectomy [109,110]. In fact, a better 
survival outcome was seen in O blood type patients of pancreas and breast 
cancers [111,112], but no specific type of blood group was statistically associated 
to bladder tumour patient’s outcome [109,110].  
Lewis antigens 
 
Several authors have studied the expression of the Lea antigen in bladder 
tumours. Cordon-Cardo et al. (1988) referred that there were no alterations in this 
antigen expression patterns with malignant transformations in the bladder [113]. 
However, Limas et al. (1985) had already reported significantly lower expression 
of Lea in healthy urothelium (6%), when compared to invasive tumours of the 
bladder (35%) [106]. Also Juhl et al. (1986) found a high expression of Lea antigen 
in invasive bladder carcinomas (93%) [114]; both studies strongly suggest that the 
expression of Lea is associated with a malignant phenotype of bladder tumour 
[114, 106].  
The sialylated form of Lea, the SLea antigen or Ca 19-9, commonly used in 
pancreatic cancer as a serum marker [115] has been observed in bladder 
dysplasia, CIS, non-invasive and invasive carcinomas of the bladder [116]. With 
the purpose of diagnose urothelial carcinoma of the bladder by measuring Ca 19-9 
level in the urine, Pal et al. (2011) studied 47 patients with confirmed tumour and 
50 controls. When compared with normal urothelium, Ca19-9 urine levels were 
significantly higher in bladder tumour patients. According to their results, Ca19-9 
may be a useful non-invasive test to diagnose the urothelial carcinoma of the 
bladder [117]. Another study compared Ca19-9 levels in serum and in urine of 
patients with low grade urothelial bladder tumours. Its findings suggested that 
urinary CA 19-9 is a better screening parameter with optimum sensitivity and 
specificity than its serum counterpart for diagnosis of low grade and early stages 
of transitional cell carcinoma of urinary bladder, being also considered as a 
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prognostic marker [118]. In contrast with these results, Washino et al. (2011) and 
Hegele et al. (2010) did not found Ca 19-9 a useful tumor marker when tested in 
serum or in tumour. However, they did not exclude its presence in bladder 
carcinomas [119,120].   
Neoexpression of the Lewis X antigen (Lex; which is absent in normal urothelium) 
is noted in over 85% of urothelial bladder cancers regardless of tumour stage and 
grade [121]. This corroborates the Cordon-Cardo et al. (1988) studies that 
compared the expression pattern of this antigen in healthy urothelium with invasive 
carcinomas and CIS [113]. Particularly, the study revealed that none of the healthy 
urothelium specimens expressed Lex; conversely, this antigen was observed in 
invasive carcinomas of the bladder (100%) and CIS (79%). Furthermore, the 
authors suggested that Lex expression could be a reliable indicator of malignant 
transformation of bladder urothelium [113].  
Sialy Lex (SLex), the sialylated form of Lex, has also been studied in bladder 
urothelium. According to Numahata et al. (2002) the SLex antigen is present in 
invasive tumours but absent in noninvasive ones [122]. Moreover, patients who 
had mAb SNH3 (an anti-SLex monoclonal antibody) positive tumours had 
significantly lower survival rates, compared with patients who had SNH3 negative 
tumours. Futhermore, the SNH3 staining of tumours was not correlated with 
tumour grade (2 or 3) or pT (pT2-T4) classification but was strongly correlated with 
the presence of lymph node metastasis at the time of first clinical examination 
[122]. These findings were corroborated by Kajiwara et al. (2005) that observed 
altered SLex patterns in all of the invasive carcinomas specimens studied, namely 
renal pelvis, ureter and urinary bladder. Both studies referred altered SLex 
expression as a predictor of invasive potential and metastatic outcome [122,123].  
 
Thomsen-Friedenreich related antigens 
 
Increased levels of truncated O-GalNAc glycans have also been observed in BC. 
Of note, only a few reports were published, almost all more than 20 years ago. 
[74,124]. These studies have demonstrated that T and Tn antigens are over-
expressed in bladder carcinoma cells, compared to normal cells which practically 
do not express these glycans [74,84]. In particular, Limas C. et al. (1986) 
evaluated by immunohistochemistry the expression of the T antigen in biopsies 
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from 56 BC patients at various stages of the disease, including normal and pre-
neoplastic bladder disease. These authors demonstrated a growing expression of 
T antigen through healthy (0%), pre-neoplastic (14%) and neoplastic (11-65%) 
urothelium [125]. According to their results the spontaneous expression of T 
antigen is associated with the aggressiveness of the tumour; being this expression 
correlated with a greater metastatic potential [125]. Tn, STn, T  and cryptic-T (ST 
comprising S6T, S3T and DST) antigens were evaluated by Langkilde et al. (1992) 
in patients with initially non-invasive carcinomas whom experienced different 
courses of the disease [126]. No association was found between Tn and STn 
antigens and tumour progression to invasion. Nevertheless, 70% of the patients 
that expressed T antigen and 39% of those whom expressed cryptic-T antigen 
experienced invasive recurrence, while the other patients did not [126]. The same 
authors, few years later studying primary non-invasive and superficially invasive 
human urinary bladder tumours reinforced the idea that there is a correlation 
between T-antigen expression and recurrence or progression of initially non or 
superficially invasive tumours [127]. 
Altogether, these findings suggest that BC patients whom spontaneously express 
T antigen present invasive recurrences more frequently than those who do not 
express this antigen. Furthermore, T antigen expression seems to correlate with 
the metastatic potential and aggressiveness of the tumour [125-127].  
Yamada et al. (1988) have demonstrated that cryptic T (ST) antigen is normally 
expressed by noninvasive or superficially invasive (Ta or T1) urothelial papillary 
tumours [128]. These authors reported that ST expression was partially or 
completely lost in tumours that showed malignant progression after frequent 
recurrences. More recently, Videira et al. (2009) demonstrated that ST3Gal.I plays 
a major role in the sialylation of the T antigen in BC [74]. According to this study, 
the overexpression of ST3Gal.I seems to be part of the initial oncogenic 
transformation of bladder cells and should be considered when predicting cancer 
progression and recurrence [74].  
The studies presented so far suggest that both pre-neoplastic lesions and bladder 
tumours express altered glycosylation patterns. Some studies also point out that 
alterations in cell glycosylation patterns are generally associated with tumour 
grade, invasion and metastasis. Therefore aberrant glycosylation correlates with 
poor prognosis [122,125-128]. Following this thought, targeting these antigens 
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may allow the determination of the malignant potential of the tumour and the 
control of the disease. Nevertheless, these studies have been performed in small 
and heterogeneous patient cohorts using different antibodies. As such, a careful 
interpretation of the results should be conducted, since several antibodies have 
affinity for similar structurally-related glycosylated structures [122,129]. Different 
methodologies have been used, which may also contribute to biased 
interpretations.  
Sialyl-Tn 
 
Despite the cancer-associated nature of the STn antigen, few studies have been 
presented in the context of BC. Langkilde et al. (1992) conducted the first study 
involving this antigen on a series of high-grade urothelial cell carcinomas, using 
normal mucosal specimens of patients with non-malignant bladder urologic 
diseases as controls [126]. The authors reported that STn was not expressed by 
the control group and showed a very restricted pattern of expression in bladder 
tumours. Moreover, no association with recurrence and progression was observed 
[126]. However, four years later, in vitro studies have demonstrated that STn 
expression enhanced the invasion capability of bladder cancer cells [130].  
Still, little information is available about the biological and clinical significance of 
STn expression in BC. In spite of other tumour types, there are no consistent 
studies in bladder that demonstrate its association with invasion and metastasis. 
As such it is of prime importance to investigate the relevance of this antigen in BC 
models and to encourage the development of therapeutics targeting this antigen. 
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Based on previous knowledge, the main objective of this thesis is to understand 
the biological and clinical significance of sialyl-Tn expression in bladder cancer, 
aiming to improve patient stratification and guide the design of novel therapeutics. 
In order to accomplish it, STn was studied in three dimensions: relating it with the 
clinical outcome, with the tumour treatment and with tumour biology. 
 
The specific aims of this thesis are: 
 
- Evaluate the pattern of STn expression in bladder tumours and its 
association with clinicopathological variables and disease prognosis, 
envisaging to improve patient stratification; 
- Determine the biological significance of STn expression in bladder cancer, 
namely in cell proliferation, invasion and migration; 
- Evaluate the role of STn in the context of BCG immunotherapy outcome, 
generally used as adjuvant therapy in patients with non-muscle invasive 
tumours showing a  high risk of progression to muscle-invasion; 
- Determine associations between STn expression and the activation of the 
PI3K/Akt/mTOR cascade, associated with poor prognosis in bladder 
cancer. 
 
To accomplish the first objective, a preliminary study was performed in small 
series of UBC (69 patients), of several grades and stages. STn was accessed by 
immunohistochemistry. Furthermore, a glycoengineered cell model expressing 
STn was developed and used to access the role of the antigen in cell motility and 
invasion. The results are presented on Chapter 3.1, in Paper I entitled 
“Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced 
bladder tumours”. 
After the previous results (Paper I), and because STn is known to influence both 
cell-cell interactions and immune response, it seemed to be important to evaluate 
the influence and the predictive value of this antigen in the context of BCG 
immunotherapy. Regarding the evaluation of the tumour-associated carbohydrate 
antigen STn role in BCG immunotherapy, the group work is presented in Chapter 
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3.2, in Paper II, entitled “Response of high-risk of recurrence/progression bladder 
tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy”. 
Both previous findings resulted in the final objective that was achieved when STn 
status was related with other biological markers like the ones involved in the 
mammalian target of rapamycin (mTOR) cascade. The mTOR signaling cascade 
is a key pathway in the progression of different cancers. In bladder cancer, several 
groups showed that mTOR activation correlated with reduced disease specific 
survival and increased pathologic staging [131]. In Chapter 3.3, the influence of 
STn in the mTOR cascade, as well as its possible importance in bladder cancer 
discrimination of potential response to a subset of therapeutics was described in 
Paper III, entitled “Abnormal protein glycosylation and activated PI3K/Akt/mTOR 
pathway: role in bladder cancer prognosis and targeted therapeutics”. 
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 3.1- Sialyl Tn expression and advanced bladder 
tumours 
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in advanced bladder tumours 
 
 
JA Ferreira, P Videira, L Lima, S Pereira, M Silva, M Carrascal, PF Severino, E 
Fernandes, A Almeida, C Costa, R Vitorino, T Amaro, MJ Oliveira, CA Reis, F 
Dall’Olio, F Amado, LL Santos 
 
Molecular Oncology 2013 
Jun;7(3):719-31. 
doi: 10.1016/j.molonc.2013.03.001.  
 
 
Overexpression of tumour-associated carbohydrate antigen
sialyl-Tn in advanced bladder tumours
Jose Alexandre Ferreiraa,b,*,1, Paula A. Videirac,**,1, Luıs Limab,d,e,f,
Soﬁa Pereirab,g, Mariana Silvac, Mylene Carrascalc, Paulo F. Severinoc,h,
Elisabete Fernandesb, Andreia Almeidaa,b, Ceu Costab,g, Rui Vitorinoa,
Teresina Amaroi, Maria J. Oliveiraj,k,l, Celso A. Reisd,k,m, Fabio Dall’Olioh,
Francisco Amadoa,n, Lucio Lara Santosb,g,o
aQOPNA, Mass Spectrometry Center, Department of Chemistry, University of Aveiro, Aveiro, Portugal
bExperimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Porto, Portugal
cCEDOC, Departamento de Imunologia, Faculdade de Cie^ncias Medicas, FCM, Universidade Nova de Lisboa, Lisboa,
Portugal
dInstitute of Biomedical Sciences of Abel Salazar, University of Porto, Porto, Portugal
eNucleo de Investigac¸~ao em Farmacia e Centro de Investigac¸~ao em Saude e Ambiente (CISA), Health School of the
Polytechnic Institute of Porto, Porto, Portugal
fLPCC, Research Department-Portuguese League Against Cancer (NRNorte), Portugal
gHealth School of University of Fernando Pessoa, Porto, Portugal
hDepartment of Experimental, Clinical and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
iDepartment of Anatomic Pathology, Hospital Pedro Hispano, Matosinhos, Portugal
jINEB e Institute of Biomedical Engineering, Porto University, Portugal
kDepartment of Pathology e Oncology, Faculty of Medicine, Porto University, Portugal
lDepartment of Biology, Faculty of Sciences, Porto University, Portugal
mInstitute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
nSchool of Health Sciences, University of Aveiro (ESSUA), Portugal
oDepartment of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal
A R T I C L E I N F O
Article history:
Received 26 February 2013
Received in revised form
11 March 2013
Accepted 12 March 2013
Available online 21 March 2013
Keywords:
Sialyl-Tn
Bladder cancer
Glycosylation
ST6GalNAc.I
A B S T R A C T
Little is known on the expression of the tumour-associated carbohydrate antigen sialyl-Tn
(STn), in bladder cancer. We report here that 75% of the high-grade bladder tumours, pre-
senting elevated proliferation rates and high risk of recurrence/progression expressed STn.
However, it was mainly found in non-proliferative areas of the tumour, namely in cells
invading the basal and muscle layers. STn was also found in tumour-adjacent mucosa,
which suggests its dependence on a ﬁeld effect of the tumour. Furthermore, it was not ex-
pressed by the normal urothelium, demonstrating the cancer-speciﬁc nature of this anti-
gen. STn expression correlated with that of sialyltransferase ST6GalNAc.I, its major
biosynthetic enzyme. The stable expression of ST6GalNAc.I in the bladder cancer cell
line MCR induced STn expression and a concomitant increase of cell motility and invasive
capability. Altogether, these results indicate for the ﬁrst time a link between STn
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expression and malignancy in bladder cancer. Hence, therapies targeting STn may consti-
tute new treatment approaches for these tumours.
ª 2013 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
Bladder cancer, the ﬁfth most common cancer in Western so-
ciety, is a growing concern, owing to increased incidence dur-
ing the past years (Ploeg et al., 2009; van Rhijn et al., 2009).
Most of the newly diagnosed bladder cancer cases are superﬁ-
cial, or low-grade non-muscle invasive papillary tumours, be-
ing conservatively treated by complete transurethral
resection of the tumour (Babjuk et al., 2012). However, approx-
imately half of the patients show a high-percentage of recur-
rences and an elevated risk of progression to muscle
invasive disease, which correlates with poor prognosis
(Hussain et al., 2009). The risk of recurrence and/or progres-
sion is mostly determined by clinicopathological features
(Babjuk et al., 2012). According to the European Organization
for Research and Treatment of Cancer (EORTC), this group in-
cludes high grade (HG) papillary tumours and carcinoma in
situ (CIS) and those with multifocal or recurrent lesions
(Babjuk et al., 2012). The evaluation of the nuclear protein
Ki-67 (Ki-67 proliferation index), an established marker of
cell proliferation, is often used to enhance the prognostic ac-
curacy of risk classiﬁcation given by clinicopathological fea-
tures (Margulis et al., 2009; Santos et al., 2003), since it is
considered a surrogate biomarker of bladder cancer aggres-
siveness, disease recurrence and progression (Margulis et al.,
2009; Santos et al., 2003).
Tumour resection followed by a schedule of intravesical in-
stillations with live attenuated strains of Mycobacterium bovis
(Bacillus CalmetteeGuerin, BCG) is the standard adjuvant
therapeutic option for high-risk of recurrence/progression
bladder tumours (Askeland et al., 2012; Babjuk et al., 2012).
Although BCG has improved themanagement of high-risk pa-
tients, 30e40% of cases either show intolerance or relapse af-
ter treatment (Yates and Roupret, 2011). Consequently, these
patients require life-long follow-up and repeated courses of
treatment making bladder cancer the costliest to treat among
solid tumours (Askeland et al., 2012; Dovedi and Davies, 2009;
Sievert et al., 2009). Upon therapeutic failure and/ormuscle in-
vasion, cystectomy is advocated for oncological control
(Askeland et al., 2012; Dovedi and Davies, 2009; Sievert et al.,
2009). Furthermore, at the moment there is a lack of speciﬁc
biomarkers to target aggressive cell phenotypes and direct
molecular-based therapy, whichmay be used to avoid preven-
tive cystectomy (Dovedi and Davies, 2009).
Vaccines using tumour-associated glycans, in association
with immunological boosters, are emerging as potential ther-
apeutic strategies against cancer (Hakomori, 2001;
Lakshminarayanan et al., 2012; Ryan et al., 2010; Sorensen
et al., 2006). In the forefront of these antigens is sialyl-Tn
(STn; Neu5Aca2-6GalNAca-O-Ser/Thr) (Gilewski et al., 2007;
Julien et al., 2009; Miles et al., 2011). STn has been mostly
observed in tumour-associatedmucins due to their high num-
ber of potential O-glycosylation sites (Clement et al., 2004;
Conze et al., 2010; Julien et al., 2006; Marcos et al., 2011;
Pinto et al., 2012). However, integrins (Clement et al., 2004)
and CD44 (Julien et al., 2006), among other proteins, may
also carry this posttranslational modiﬁcation. Overexpression
of STn antigen has been detected in breast (Leivonen et al.,
2001), oesophagus (Ikeda et al., 1993), colon (Itzkowitz et al.,
1989), pancreas (Kim et al., 2002), stomach (David et al., 1996;
Marcos et al., 2011), endometrium (Inoue et al., 1991), and
ovary (Numa et al., 1995) carcinomas, whereas low or no
expression was observed in the respective normal tissues.
STn overexpression was also reported in several cancer pre-
cursor lesions, such as esophageal dysplastic squamous
epithelia (Itoh et al., 1996), gastric intestinal metaplasia
(Baldus et al., 1998; Ferreira et al., 2006) and colonic moderate
dysplasia (Cao et al., 1997).
STn is known to inﬂuence cell recognition by the immune
system (Angata et al., 2007), affect processes as cell cycle,
apoptosis, and actin cytoskeleton dynamics, decrease
cellecell aggregation and increase extra-cellular adhesion,
migration, invasion (David et al., 1996; Julien et al., 2006,
2005; Pinho et al., 2007) and metastization (Ozaki et al.,
2012). In linewith these observations, STn positive (STnþ) cells
have been frequently observed at the invasion front of tu-
mours and in peritoneal and pleural effusions in ovarian can-
cer patients; yet they are less common in metastatic lesions
than in primary tumours (Davidson et al., 2000). In gastric car-
cinomas, STn was correlated with the depth of invasion and
metastization (Ikeda et al., 1993), and thus poor prognosis
(Terashima et al., 1998). Conversely, STn was not correlated
with the depth of invasion in studies concerning colorectal
(Itzkowitz et al., 1989; Ogata et al., 1998) and breast cancers
(Schmitt et al., 1995). However, some contradicting results
have been presented regarding its associationwithmetastasis
and decreased survival in these cancers (Julien et al., 2012).
Hence, a recent review suggests that the biological role of
STn in tumour development may be dependent on each can-
cer type or sub-type (Julien et al., 2012).
Despite these observations, there is little information
regardingSTn in thecontext of bladder cancer. Given its clinical
relevance and the fact that there are available therapies based
on this antigen,weaddressed thepresenceofSTn inbladder tu-
mours and the mechanisms underlying its expression.
2. Materials and methods
2.1. Patient and sampling
Formalin-ﬁxed, parafﬁn embedded (FFPE) tissues were pro-
spectively collected from 69 patients, mean age of 69 years
(age range 45e89), who underwent transurethral resection
(TUR) of the bladder tumour in the Portuguese Institute for
Oncology of Porto (IPO-Porto, Portugal), between July 2011
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and May 2012. Based on urothelial carcinoma grading and
staging criteria of theWorld Health Organization (WHO), three
different groups were considered (Table 1), low-grade (LG,
n ¼ 24) and high-grade HG non muscle-invasive (NMIBC,
n ¼ 26) and muscle-invasive (MIBC, n ¼ 19) bladder cancers.
Of HG NMIBC, 21 were papillary tumours and 5 were carci-
noma in situ (CIS). None of these patients had received prior
adjuvant therapy. Six normal urothelium tissues of necrop-
sied male individuals without bladder cancer history, within
the same mean of age range, were also included.
Additionally, FFPE tissues from 16 radical cystectomy cases
including the main lesion in each specimen, responsible for
therapeutic decision, the adjacent mucosa, which may or
may not include a concomitant tumour, and the ureter repre-
senting a distant mucosa, were also studied. Mucosa without
visible histopathological alterations was deﬁned as “histolog-
ically normal” mucosa.
All procedures were performed under the approval of the
Ethics Committee of IPO-Porto, after patient’s informed con-
sent. All clinicopathological information was obtained from
patients’ clinical records.
2.2. Tissue expression of STn and Ki-67
FFPE tissue sections were screened for STn and Ki-67 by immu-
nohistochemistry using the avidin/biotin peroxidase method.
Brieﬂy, 3 mm sections were deparafﬁnised with xylene, rehy-
drated with graded ethanol series, microwaved for 15 min in
boiling citrate buffer (10 mM Citric Acid, 0.05% Tween 20, pH
6.0), and exposed to 3% hydrogen peroxide in methanol for
20 min. The expression of STn was then evaluated using anti-
STn mouse monoclonal antibody, clone TKH2 (Kjeldsen et al.,
1988), that identiﬁes both single and clustered STn residues
(Ogata et al., 1998), whereas Ki-67 was evaluated using mono-
clonal mouse anti-human Ki-67 antibody, clone MIB-1 (Dako).
After blockagewith BSA (5% in PBS), the antigenswere identiﬁed
withVectastainEliteABCperoxidase kit (Vector Lab) followedby
incubationwith 3,3-diaminobenzidine tetrahydrochloride (DAB,
Dako). Finally, the slides were counterstained with haematoxy-
lin for 1 min. Positive and negative control sections of intestinal
metaplasiawere tested inparallel. Thenegative control sections
were performed by adding BSA (5% in PBS) devoid of primary
antibody. STnþ tissues were also treated with a neuraminidase
from Clostridium perfringens (SigmaeAldrich) as previously
described by Marcos et al. (2011) in order to remove the sialic
acid. The desialyated samples were thereafter screened for
STn.TheO-acetylationofNeu5Ac residues inSTnwasevaluated
after treatment with 100 mM NaOH at room temperature for
30 min as described by Ogata et al. (Ogata et al., 1998) prior to
immunohistochemistry with antibody TKH2.
A semi-quantitative approach was established to score the
immunohistochemical labelling based on the intensity of
staining and the percentage of cells that stained positively.
The STn and Ki-67 expression were assessed double-blindly
by two independent observers and validated by an experi-
enced pathologist. Whenever there was a disagreement, the
slides were reviewed, and consensus was reached. Tumours
were classiﬁed as proliferative whenever Ki-67 expression
was higher than 18%, as described by Santos et al. (Santos
et al., 2003).
2.3. Cell lines culture
The human bladder cancer cell line MCR and the transduced
variants of MCR (MCRnc and MCRSTnþ), were grown as
described by Videira et al. (2009b).
2.4. Generation of STnþ bladder cancer cells
MCR cells were transduced with a retroviral vector generated
with the ViraPower Lentiviral Expression System (Invitro-
gen), according to manufacturer’s instructions. The whole
coding region of human ST6GalNAc.I was PCR ampliﬁed and
cloned in the pLenti6/V5 Directional TOPO cloning vector
which drives the expression of inserted genes through the
CMV promoter. A negative control retroviral vector was pre-
pared with an empty plasmid. After transduction with nega-
tive control- or ST6GalNAc.I-expressing vectors, MCR cells
were selected with 4 mg ml1 blasticidin. An additional immu-
nomagnetic enrichment of the STnþ cells was performed by
using mouse anti-STn (HB-STn1 clone from Dako), followed
by the secondary antibody anti-mouse IgG associated to para-
magnetic microbeads (Miltenyi Biotec). The stable transduc-
tion of the enzyme was conﬁrmed by evaluation of
ST6GalNAc.I expression and activity. STn expression was
Table 1 e STn expression in the healthy urothelium and in non-
muscle invasive (NMIBC) and muscle invasive (MIBC) bladder
cancers of different clinicopathological natures.
Total STn expression
Normal urothelium 6
e 6 (100%)
þ e
þþ e
þþþ e
Total STnþ 0 (0%)
NMIBC 50
Low-grade papillary tumours 24
e 19 (79%)
þ 5 (21%)
þþ e
þþþ e
Total STnþ 5 (21%)
High-grade (CIS þ papillary tumours) 26
Carcinoma in situ (CIS) 5
e 4 (80%)
þ 1 (20%)
þþ e
þþþ e
Total STnþ 1 (20%)
High-grade papillary tumours 21
e 5 (24%)
þ 9 (43%)
þþ 4 (19%)
þþþ 3 (14%)
Total STnþ 16 (76%)
MIBC 19
e 5 (26%)
þ 11 (58%)
þþ 2 (11%)
þþþ 1 (5%)
Total STnþ 14 (74%)
e: No reactivity;þ:15%;þþ: 15e30%;þþþ: 30e45% of the tumour.
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determined by analysis of the mean ﬂuorescence intensity
(MFI)  SE through ﬂow cytometry analysis using monoclonal
antibody TKH2.
2.5. Evaluation of STn expression in cell lines
For phenotypic characterization, cells were stained with 1:50
diluted anti-STn TKH2 monoclonal antibody for 16 h at 4 C,
and 1:100 diluted goat ﬂuorescein isothiocyanate (FITC)-
labelled anti-mouse IgG (Dako) for 15 min at 4 C in the dark
and then acquired in a FacsCalibur Flow cytometer (Becton
Dickinson). Data were analysed using the WinMDI v2.9 soft-
ware (The Scripps Research Institute, San Diego, CA, USA).
2.6. Analysis of ST6GalNAc.I expression
RNAextraction fromFFPE sectionswas performed after depar-
afﬁnizationof the tissueusingAbsolutelyRNAFFPEkit (Agilent
technologies) while for cell lines it was used the GenElute
Mammalian Total RNA Puriﬁcation kit and DNAase treatment
(Sigma), according to themanufacturer’s instructions. The pu-
rity of RNA extracts was determined based on the A260/A280 ra-
tio. Only ratios between 1.9 and 2.1 were considered further.
Approximately 250e500 ng of total RNA (1 mg for cell lines)
was converted by reverse transcription into cDNA, using the
random-primers-based High Capacity cDNA Archive Kit
(Applied Biosystems). The expression levels of ST6GalNAc.I
were determined by TaqMan assay (Applied Biosystems), the
reference sequences detected by each primer/probe set and
the Assay ID provided by the manufacturer were the
following: ST6GalNAc1 (NM018414.2/Hs00300842_m1). Real
time PCR was performed in a 7500 Fast Real-Time PCR System
using the TaqMan Universal PCR Master Mix Fast from
Applied Biosystems, as described previously by Videira et al.
(2007, 2009a). During the cDNA exponential ampliﬁcation the
product formation was proportional to the ﬂuorescence emis-
sion resulting from the TaqMan probe degradation (van der
Velden et al., 2003). The ST6GalNAc.I mRNA levels were
normalized for the expression of b-actin, which was taken
as a suitable endogenous control for bladder cancer cells
(Videira et al., 2007). The relativemRNA levels were calculated
by adapting the 2DDCt formula (Livak and Schmittgen, 2001).
2.7. Evaluation of ST6GalNAc.I activity
MCR cell pellets were homogenized in H2O and the protein con-
centration was determined using the RC-DC protein quantiﬁca-
tion kit (BioRad) according to the manufacturer’s instructions.
Sialyltransferase activity was assayed in whole cell homoge-
nates as previously described by Dall’Olio et al. (1997) with
some modiﬁcations. Brieﬂy, the reaction mixture contained
80 mM sodium cacodylate buffer pH 6.5, 0.5% Triton X-100,
6 mg ml1 of asialo bovine submaxillary mucin (ABSM, prepared
by acid desialylation of BSM) as acceptor substrate, 30 mM
(1280 Bq) of CMP-[14C]Sia (Amersham) and 2 mg ml1 of homoge-
nate proteins. Endogenous controls were prepared in the
absence of acceptor substrate. The enzyme reactionswere incu-
bated at 37 C for 2 h and the acid insoluble radioactivity was
measured as previously described by Dall’Olio et al. (1997). The
incorporation on endogenous substrates was subtracted.
2.8. Cell proliferation measurement
To study their proliferative capacity, cells were labelled with
CellTrace CFSE Cell Proliferation Kit (Invitrogen). The MCR
cells were resuspended into medium at ﬁnal concentration
of 1  106 cells ml1 and incubated with 10 mMCFSE, following
the manufacturer’s instructions. Subsequently, the CFSE-
labelled cells were seeded into 24-well microplates, incubated
in a 5% CO2 incubator at 37 C and harvested at 24, 48, 72 and
96 h post-culture. Flow cytometry using a FACSCalibur (Bec-
toneDickinson) was performed and the data collected were
analysed with ModFit LT 3.2 software (Verity Software House,
Topsham, ME), allowing to assess the cell proliferation index
(PI). The PI represents the average number of cells that were
originated from a single cell of the parental generation. The
parental generation was set based on the analysis of data ob-
tained from the cells corresponding to the 24 h of culture.
2.9. Analysis of cell motility using a wound-healing
assay
Cell motility was tested in a wound-healing migration assay.
MCR cells were seed into 12-wellmicroplates and grown to con-
ﬂuency. A scratch was made in the monolayer with a sterile
200ml pipette tip.Afterwounding, thesuspendedcellsanddebris
were washed away and freshmediumwas added. At 0 and 24 h
after wounding, scratched regions were photographed with an
inverted microscope equipped with a digital camera.
2.10. Invasion assay
InvasionassayswereperformedusingBDBiocoatMatrigel in-
vasion chambers, comprised by an 8-mmdiameter pore size ﬁl-
ter coated with a thin layer of matrigel, and placed in a two-
compartment system in a 24-well plate. Prior to each experi-
ment, ﬁlters were re-hydrated in serum-free DMEM medium
for 2 h at 37 C. After detachment of subconﬂuent cells with
trypsin/EDTA, cellswere suspended in culturemediumsupple-
mentedwith5% inactivatedFBS, countedandseededontheup-
per side of thematrigel-coated ﬁlter at a density of 5 104 cells/
well. After 24 h at 37 C, ﬁlters were ﬁxed in 4% paraformalde-
hyde and non-invading cells, present on the upper side, were
completely removed, to facilitate analysis. Cells that had
invaded the underside of the ﬁlters were mounted in
Vectashieldþ40,6-diamidino-2-phenylindole (DAPI, Vector Lab-
oratories, CA, USA), and visualized through a Zeiss Axiovert
200M ﬂuorescence microscope (Carl Zeiss, Germany). Invasive
cellswere scored inat least 12microscopicﬁelds (20objective)
when DAPI-counterstained nuclei passed through the ﬁlter
pores. Results are presented asmeans SD for each sample. In-
vasion levels are expressed as a ratio of the results obtained
with the mock-transfected control cell line.
2.11. Statistical analysis
Statistical analysis was performed using the Student’s T-test
for unpaired samples. Differences were considered to be sig-
niﬁcant when p < 0.05. A chi-square test was used to analyse
correlations between clinicopathological features and STn
and Ki-67 expressions.
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3. Results
3.1. Expression of STn in bladder tumours
STn expression in bladder tumours was evaluated by immu-
nohistochemistry using mouse monoclonal antibody clone
TKH2. As shown in Table 1, STn is not expressed in the healthy
urothelium; conversely 46% of the bladder tumours presented
cells with STn membrane and cytoplasmic staining (32/69)
(Figure 1), demonstrating the tumour-speciﬁc nature of this
antigen. The removal of sialic acids from the tissue sections
with a a-neuraminidase impaired the recognition by TKH2
and conﬁrmed STn expression.
STn expression was lower in low-grade (LG) NMIBC (21%
STnþ tumours; Figure 1AeB) compared to high-grade lesions
(HG; 67%), which include papillary tumours (76% STnþ tu-
mours; Figure 1CeE), CIS (20% of STnþ tumours; Figure 1F),
and MIBC (74% STnþ tumours; Figure 1GeH). Noteworthy,
STn was absent from the majority of CIS (4/5; 80%) and
showed an expression comparable to LG tumours. Altogether,
these results highlight an association between the STn anti-
gen and high grade NMIBC ( p < 0.002; Figure 2) as well as
with muscle invasive tumours ( p < 0.03; Figure 2).
TheO-acetylationof sialic acid residuespreventsTKH2 from
recognizing STn antigens in certain tissues (Ogata et al., 1998).
To exclude this possibility in bladder cancer, the slides were
chemically de-O-acetylated prior to immunohistochemistry.
This procedure did not alter STn expression patterns demon-
strating that STnantigenswerenot encryptedbyO-acetylation.
3.1.1. Pattern and extension of STn expression in bladder
tumours
The STn antigen presented a focal expression that for the ma-
jority of the STn positive cases (26/36) did not exceeded 15% of
the tumour section (Table 1). Furthermore, in 25% of the STn
positive cases (9/36) the antigen was detected in less than 5%
of the tissue (data omitted fromTable 1).Higher expressionpat-
terns were restricted to HG papillary NMIBC, where 27% of the
cases (7/26) presented STn levels between 15% and 45% of the
tumour section (Table 1) and locally diffuse staining
(Figure 1C, D, G). STn was mainly observed in basal layer cells
(75%of STnþ cases; Figure 1A,CeE), but it couldbe alsodetected
throughout the papillae (Figure 1CeE) and cells of the luminal
surface (Figure 1F) in cases presenting locally diffuse staining.
STn was further observed in cells invading the basal (50% of
STnþ of HG NMIBC; Figure 1CeE, G) and muscle layers (57% of
STnþMIBC; Figure 1G, H), suggesting a role in invasion.
3.1.2. STn antigen expression in advanced tumours and in the
surrounding areas
TheSTnantigenwas also evaluated ina series of radical cystec-
tomy specimenswhich included the tumourused for therapeu-
ticdecision (termed“maintumour” inFigure3) and thetumour-
adjacentmucosa. The ureterswere included as distantmucosa
(Figure3). Inagreementwith theobservations fromTable1, STn
was detected in 69% (11/16) of all main tumours as well as in
their adjacent mucosa (Figure 3), independently of their histo-
logical classiﬁcation. Noteworthy, STn was absent from 90%
of the distant mucosas of STn positive cases; the only
exceptions being a ureter with pre-neoplastic and another
with a neoplastic lesions (Figure 3). These results point out
that the STnþ tumour-adjacentmucosamay displaymolecular
changes similar to those of themain lesions. Thus, this antigen
maybeuseful asamarkerof ﬁeld carcinogenesis in thebladder.
3.2. Expression of ST6GalNAc.I in bladder tumours
The presence of STn has been strongly associated with the
overexpression of ST6GalNAc.I in several human malig-
nancies. To assess this event in bladder tumours,mRNA levels
of ST6GalNAc.I gene were analysed and normalized in relation
to b-actin, which proved to be a stable expressed gene in pre-
vious studies concerning bladder tumours (Videira et al.,
2007). As shown by Figure 4, low gene expression levels were
detected in tumours that did not express STn. In addition,
the levels of ST6GalNAc.I increased with the expression of
STn, and were signiﬁcantly higher in the tumours with STn
expression superior to 15%. Figure 4 also shows that this
behaviour was similar in LG and HG tumours. However, as a
result of higher STn expression, the average ST6GalNAc.I
mRNA levels were more elevated in HG (53%) tumours than
LG (9%). These observations suggest that overexpression of
ST6GalNAc.I gene is one of the main events leading to STn
expression in bladder tumours.
3.3. STn expression and tumour proliferation
As shown above, the expression pattern of STn correlates with
HG tumours, known to present elevated proliferation rates
(Margulis et al., 2009; Santos et al., 2003). To assess a possible as-
sociationbetweenSTnandproliferation,24cases fromtheinitial
series of 69 bladder tumours, comprehending 12 LG and 12 HG
tumours (7NMIBC,noneof themCIS,and5MIBC),werescreened
for STnandKi-67 expression. Tumours presenting Ki-67 expres-
sion superior to 18% were classiﬁed as proliferative. As high-
lighted by the graphical matrix in Figure 5A, 8% (1/12) LG and
75% (9/12) HG cases showed elevated Ki-67, conﬁrming the
higher proliferation of HG tumours ( p < 0.0012). Similarly,
Figure 5A also shows an association between proliferative phe-
notypesandSTnexpression ( p< 0.001).However, in all STnpos-
itive cases, the examination of sequential sections revealed that
STnantigenexpressionwasmainly seen inareas thatdidnotex-
press Ki-67 (Figure 5A), although some overlap was present in
25% of the cases (3/12; Figure 5B). This indicates that the STn an-
tigen is mostly expressed in non-proliferative areas of the
tumour. Nevertheless, the majority of the non-proliferative tu-
mours also did not express STn (12/14), demonstrating an inter-
dependence between both phenomena.
3.4. In vitro assessment of the biological signiﬁcance of
STn expression
3.4.1. Development of a high-grade bladder cancer cell line
overexpressing STn
To further corroborate the role of ST6GalNAc.I in the expres-
sion of STn antigen by bladder cancer cells, we induced the
overexpression of ST6GalNAc.I in a bladder cancer cell line.
The MCR bladder cell line, that showed negligible expression
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of ST6GalNAc.I and no STn (data not shown), was transduced
with a lentivirus expressing the coding region of the human
ST6GalNAc.I gene. The obtained cell line variant, herein
named MCRSTnþ, showed markedly increased expression of
ST6GalNAc.I mRNA levels (Figure 6A). It also showed signiﬁ-
cantly higher sialyltransferase activity towards the ABSM, a
substrate for the ST6GalNac.I enzyme, when compared with
the negative control cell line (MCRnc) transduced with void
lentivirus (Figure 6A). The overexpression of STn antigen by
MCRSTnþ cell line variant was conﬁrmed by ﬂow cytometric
analysis (Figure 6B).
3.4.2. STn influence on cell proliferation, migration and
invasion
STn expression was correlated with tumours with higher pro-
liferative indexes (Figure 5). To assess the inﬂuence of STn in
Figure 1 e Expression of STn in FFPE bladder tumours. A) Low-grade papillary tumour showing a predominance of STnD cells in the basal layer;
B) Magniﬁcation which shows tumour cells with membrane and cytoplasmic STnD staining; C) High-grade papillary tumour evidencing the focal
nature of STn expression. Positive cells were found both in the basal layer and throughout the papillae; D) High-grade papillary tumour showing
locally extensive STn positivity; E) High-grade papillary tumour evidencing STnD in the basal layer; F) CIS showing STnD in the cells facing the
lumen of the bladder; G) MIBC showing locally extensive STn expression including at the muscle invasive front; H) MIBC highlighting STnD
cells invading the muscle layer.
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proliferation, MCR cells (MCRnc and MCRSTnþ) were cultured
for 48, 72 and 96 h and then evaluated in relation to their pro-
liferation index. The comparison between the two cell line
variants showed that the proliferation index of MCRSTnþ cells
was generally higher than the index of MCRnc cells, although
only statistically different at 72 h of culture ( p< 0.05; Figure 7).
However, this effectwas no longer signiﬁcant at 96 h of culture
(Figure 7).
STn positive cells were observed invading the basal and
muscle layers (Figures 1 and 2) and in the adjacent mucosa
of advanced stage bladder tumours (Figure 5), suggesting a
correlation of STn with invasion and migration. Thus, the in-
ﬂuence of STn expression in MCR cell invasion was assessed
using the Matrigel invasion assay. Our results evidence that
MCR cells transduced with ST6GalNAc.I (MCRSTnþ) are
approximately four folds more invasive than bladder cells
transduced with the negative control (MCRnc; Figure 8A).
The effect of STn expression on cell migration was estimated
by a wound-healing assay. Therefore, uniform scratches were
made in conﬂuent monolayers of MCRnc and MCRSTnþ cell
lines and the capability of the cells to migrate and ﬁll the
scratches wasmonitored. As observed in Figure 8A, by 24 h af-
ter wounding, the MCRSTnþ cells had almost completely
covered the empty space. Conversely, the negative control,
MCRnc cells, displayed a large “gap”, thus demonstrating their
lower capability to closure the wound. Our results evidence
that MCR cells expressing STn present increased invasion
and wound repair capacities.
4. Discussion
The STn antigen is highly expressed by several human carci-
nomas and preneoplastic lesions (Julien et al., 2012) and is
explored as a tumour marker in serological assays (CA72-4)
(Reis et al., 2010).
Despite the clinical relevance of STn in human malig-
nancies, scarce information is available about its role in
bladder tumours. Over twenty years ago, Langkilde et al.
(1992) addressed this antigen on series of transitional cell car-
cinomas (currently classiﬁed as high-grade urothelial cell car-
cinomas according to current WHO guidelines (Babjuk et al.,
2012)). Normal mucosal biopsy specimens from patients
with non-malignant bladder urologic diseases were included
as controls. According to the authors, STn was not expressed
by the control group, showed a very restricted pattern of
expression in bladder tumours and no association with recur-
rence and progression. Subsequent in vitro studies found that
Figure 3 e Expression pattern of STn in radical cystectomy
specimens. Radical cystectomy specimens have been organized based
on histological grade. They include the tumour responsible by the
therapeutic decision termed “main tumour” (MT), an adjacent (AM)
and distant mucosa (DM). The graphical matrix highlights that,
whenever STn is expressed by the main tumour (13/16; 63%), it is
always present in the adjacent mucosa (13/13, 100%). One
preneoplastic and one neoplastic distant mucosa also expressed the
antigen.
Figure 2 e Association between STn expression and HG NMIBC
and MIBC. The percentage of STnD tumours was higher in HG
when compared to LG and also in MIBC when compared to NMIBC
(LG D HG). “*” p [ 0.03; “**” p [ 0.002 (Chi-square test).
Figure 4 e Association between ST6GalNAc.I and STn expression in
LG and HG bladder tumours. The graph shows that ST6GalNAc.I
expression is increased in STnD tumours and increases further for
more elevated STn expressions (>15e30% of the tumour section).
This suggests that the overexpression of ST6GalNAc.I is one of the
main mechanisms underlying the presence of STn in bladder cancers.
Furthermore, it shows this event occurs in both LG and HG tumours.
“*” p< 0.05; “**” p< 0.01 (Student’s T-test).
MO L E C U L A R O N C O L O G Y 7 ( 2 0 1 3 ) 7 1 9e7 3 1 725
mucinsMUC1, MUC2 andMAUB (mucin antigen of the urinary
bladder) isolated from bladder cancer cell lines carried STn
(Bergeron et al., 1996, 1997). However, no evidence of such
an expression was found in tumours. Herein, we readdressed
this matter and found that the STn antigen was associated
with advanced stage bladder tumours. More important, STn
was absent in the healthy urothelium, which demonstrates
its tumour-associated nature. Since this study was performed
on a recent prospective series it is not possible, at this point, to
determine correlations with disease outcome. Nevertheless,
STn was mainly expressed by HG papillary NMIBC, known
for their elevated risk of recurrence and progression tomuscle
invasive disease and MIBC that encompass an elevated risk of
metastization and present decreased overall survival (Babjuk
et al., 2012). STn expression was further associated with
elevated Ki-67, a proliferation-related molecule and a surro-
gate biomarker of increased risk to recurrence and progres-
sion in bladder tumours (Margulis et al., 2009; Santos et al.,
2003). In addition, the majority of non-proliferative tumours
did not express STn, which demonstrates that the expression
of the antigen is indeed a characteristic of proliferative tu-
mours. Still, STn was mainly detected in non-proliferative
areas of the tumours. However, the STn antigen was
frequently observed in areas of invasion of the basal andmus-
cle layers, suggesting it may be associated with the process of
cell migration and invasion. This reinforces the notion that
STn is part of amalignant bladder cancer phenotype, as previ-
ously observed for other carcinomas (Clement et al., 2004;
Julien et al., 2006; Ohno et al., 2006; Ozaki et al., 2012; Pinho
et al., 2007). We also found the STn antigen in tumour-
adjacent mucosa, which may be explained by the migration
of STnþ cells to the tumour surroundings. On the other
hand, thismay be a consequence of ﬁeld carcinogenesis previ-
ously observed in bladder cancers (Jones et al., 2005; Palmeira
et al., 2011). Nevertheless, the STn antigen holds potential as a
biomarker of bladder disseminated disease.
STn is a product of an incomplete O-glycosylation process
due to the premature O-6 sialylation of the glycoside Gal-
NAca1-O-Ser/Thr (Tn antigen) by ST6GalNAc.I (Marcos et al.,
2004). In several epithelial tumours STn results from an
increased ST6GalNAc.I expression and/or activity (Marcos
et al., 2011; Sewell et al., 2006; Vazquez-Martin et al., 2004). Pre-
vious studieshave reportedST6GalNAc.I expressionby theuro-
theliumat themRNA level (Yamamoto et al., 2003); howeverwe
andothers (Langkildeet al., 1992)havenotdetectedSTnexpres-
sion in the histologically healthy tissues. These observations
suggest either the absence of the antigen or the insufﬁcient
sensitivity of themethod. ST6GalNAc.I localization in the Golgi
apparatus and the competitive action of other glycosyltrans-
ferases for the Tn antigen may also favour the extension of
Figure 5 e Expression of STn and Ki-67 in bladder tumours. A) graphical matrix highlighting the association between proliferative tumours (Ki-
67> 18%) and STn expression in bladder tumours. HG NMIBC and MIBC were considered to be proliferative tumours and a signiﬁcant
association was found between STn expression and tumours presenting proliferation phenotypes ( p< 0.001; Chi-square test). The notation “Ki-
67/STn” in the column more to the right refers to tumours presenting areas that appear to exhibit cells expressing both Ki-67 and STn. B)
Immunohistochemistry for Ki-67 and STn highlighting Ki-67L/STnD; Ki-67D/STnL; and Ki-67D/STnD areas.
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theO-glycanchain innon-pathological conditions.Ontheother
handweshowed that the levels of STn inbladder tumourswere
correlated with the expression of ST6GalNAc.I, supporting this
as a major molecular mechanism underlying STn biosynthesis
in these tumours. Few cases presented STn expression associ-
ated with a basal level of ST6GalNAC.I, meaning that other fac-
tors may contribute to promote the biosynthesis of STn. A
disorganization of secretory organelles (Sewell et al., 2006), so-
maticmutations in thegeneCosmc, encoding amolecular chap-
erone essential for O-chain elongation (Ju et al., 2008), the
down-regulation/decreased activity of several other glycosyl-
transferases and/or the availability of sugar donors for biosyn-
thesis, may also lead to STn overexpression. The integrated
study of metabolic pathways, glycosyltransferases expres-
sion/activity, intra-cellular ultrastructures and microenviron-
mental changes may further enlighten the molecular events
leading toabnormalO-glycosylationof bladder cancerproteins.
In addition we have screened HT1376, 5637, T24 and MCR
bladder cancer cell lines and found neglectable levels of the
STn antigen (data not shown). The same was previously
observed in gastric (Ozaki et al., 2012; Pinho et al., 2007) and
breast (Clement et al., 2004; Julien et al., 2005, 2006) cancers
cell models, demonstrating that tumour cells may lose the
ability to express this antigen in vitro. Microenvironmental
factors may play a determinant role in the induction of STn
biosynthesis, yet these events remain unknown. Following
the association of STn with invasive cases, we elected the
invasive bladder cancer cell lineMCR to evaluate the biological
role of STn in these tumours.We started by stably transducing
the MCR cells with ST6GalNAc.I, which resulted in the overex-
pression of STn. The expression of STn did not promote a sig-
niﬁcant enhancement of MCR cell proliferation, which is
agreement with observations made for breast (Clement
et al., 2004; Julien et al., 2005, 2006) and gastric cancer models
(Pinho et al., 2007). These ﬁndings associatedwith the absence
of the antigen from most bladder tumours non-proliferative
areas strongly suggests that STn expression does not play a
direct role in tumour proliferation.
On the other hand, STn expression signiﬁcantly enhanced
the migration and invasive capacity of MCR cells, demon-
strating that this antigen plays an important role in bladder
cancer cell invasion, as suggested by the observation of
bladder tumours. Enhanced migration capabilities of STnþ
cells on components of the extracellular matrix, such as ﬁbro-
nectin and collagen, have been described for other cancer cell
lines (Julien et al., 2005, 2006; Pinho et al., 2007), and result,
among several factors, from impaired integrin binding
(Clement et al., 2004). In addition, STn expression has been
shown to increase the invasion potential of tumour cells
(Clement et al., 2004; Julien et al., 2006; Ohno et al., 2006;
Ozaki et al., 2012; Pinho et al., 2007), supporting a similar
role in bladder tumours. Further experiments are however
required to clarify themolecular mechanisms underlying pro-
motion of cancer cell invasion and migration. These ﬁndings
reinforce however that alterations in the glycosylation pat-
terns of cell-surface proteins may strongly interfere with
events like cellecell adhesion, cellematrix interaction,
tumour growth, motility and invasion (Dall’Olio et al., 2012).
In resume, our work comprehensively describes the
expression of the STn antigen in bladder cancer. Namely, it
demonstrates the tumour-speciﬁc nature of this type of
glycosylation and its association with advanced, highly pro-
liferative tumours, invasion and organ disseminated disease.
Thus, the evaluation of STn antigen may add valuable infor-
mation about the aggressiveness of proliferative tumours,
complementing the information given by Ki-67. Studies are
ongoing in broader retrospective series to determine the as-
sociation of STn with disease outcome and corroborate these
ﬁndings. We are also devoted to the identiﬁcation of the gly-
coproteins yielding STn, which is expected to bring insights
Figure 6 e ST6GalNAc.I mRNA expression and sialyltransferase activity in bladder cancer MCR cell lines. A) ST6GalNAc.I expression and
activity in MCR cell lines. The relative mRNA levels of ST6GalNAc.I (open bars) and sialyltransferase activity towards ABSM (grey bars) were
analysed as described in the Material and methods section. Both, ST6GalNAc.I mRNA and sialyltransferase activity towards ABSM are negligible
in negative control cells and markedly increased upon ST6GalNAc.I transduction. B) Flow cytometry analyses of transduced MCR cells. Both
negative control (MCRnc in grey histogram) and ST6GalNAc.I-transduced (MCRSTnD in open histogram) cell lines were stained with the
secondary antibody anti-Ig’s-FITC following incubation with the primary antibody anti-STn antigen. 90% of the ST6GalNAc.I-transduced cells
expressed the STn antigen (MFI[ 216). The data are shown as a mean ± standard deviation of 3 independent studies. “*” p< 0.05, “**” p< 0.01
(Student’s T-test).
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about the role of this type of glycosylation in bladder carci-
nogenesis and provide novel therapeutic vectors. The anti-
gen STn may also be monitored noninvasively in urine or
serum using as is the case for other human carcinomas us-
ing the CA72-4 test (Reis et al., 2010). This could allow
decreasing the number of cystectomies in post-surgery
follow-ups of patients with high-grade tumours, a particu-
larly critical matter for the elderly that constitute the major-
ity of the cases.
Furthermore, the STn antigen is associated to high-grade
NMIBC which currently constitutes one of the main therapeu-
tics concerns due to their elevated risk of recurrence/
progression (Babjuk et al., 2012). Adjuvant immunotherapy
with BCG has allowed to delay recurrence and decrease the
risk of progression into muscle invasive disease (Babjuk
et al., 2012); still more than half of the patients either recur
within two-years after TUR of the tumour or show intolerance
to the treatment (Askeland et al., 2012; Yates and Roupret,
2011). Due to the lack of efﬁcient therapies, upon therapeutic
failure and/or muscle invasion, the patient is faced with cys-
tectomy (Babjuk et al., 2012).
Carbohydrate antigens associated with advanced-stage tu-
mours and malignant phenotypes such as STn, are expressed
at the cell surface and, therefore, available for antibody or
lectin-mediated recognition (Neutsch et al., 2012). Thus, these
antigens may present an opportunity for the introduction of
novel therapeutics, such as selective drug-delivery approaches
(Neutsch et al., 2012) or carbohydrate-based immunotherapy
(Heimburg-Molinaro et al., 2011). An anti-cancer vaccine
named Theratope, comprehending a synthetic STn coupled to
the immunogenic carrier keyhole limpet haemocyanin has
already been developed (Julien et al., 2009; Miles et al., 2011;
Sandmaier et al., 1999). Tests in animal models and humans
for breast, ovarian, and colorectal cancers have showed that
the antigen is safe and produces a strong immune response
against these tumours (Julien et al., 2009, 2012; Miles et al.,
2011). Even though Theratope failed to improve overall survival
ofmetastatic breast cancer patients in a phase III clinical study,
the design of the study disregarded the heterogeneous STn
expression between patients (Miles et al., 2011), compromising
the outcome (Julien et al., 2012; Zeichner, 2012). Thus, Thera-
tope or other STn-based vaccine designs may constitute valu-
able therapeutic options for STn positive advanced bladder
tumours. However, given the low association of STn with
more proliferative areas of the tumour, one is led to speculate
that advanced stage bladder cancer patientsmay better beneﬁt
from the combination of anti-STn immunotherapy and anti-
proliferative drugs. Furthermore, these approaches may allow
targeting disseminated disease in the adjacent and distantmu-
cosa from the main tumour.
Figure 7 e Comparison between the proliferation capacity of MCRnc
and MCRSTnD cells. The transduced MCR cells were labelled with
CFSE and cultured for various periods of time (48, 72 and 96 h). The
cells were harvested and analysed by ﬂow cytometry with Modﬁt
software, allowing the calculation of the proliferation index, which
represents the average number of cells that was originated by a single
cell of the parent generation. At the various periods of culture,
MCRSTnD cells show a higher proliferation index than the negative
control, but this difference was only statistically signiﬁcant at 72 h of
culture. The data are presented as a mean ± standard deviation of 3
independent studies. “*” p< 0.05 (Student’s T-test).
Figure 8 e STn expression promotes MCR cells wound healing closure and invasion. A) Wound healing closure assay. Uniform scratches were
made using a 200 mL pipette tip in conﬂuent monolayers of MCRSTnD and MCRnc cells. Cells were allowed to heal and the extent of closure was
monitored by microscopic analysis. After 24 h culture, the MCRSTnD cells had almost completely covered the wound, in clear contrast to negative
control, MCRnc, where unoccupied space was still observed. B) Invasion assay. MCRSTnD and MCRnc cells were incubated for 24 h, in the
upper compartment of Matrigel invasion chambers, in complete DMEMmedium and in the absence of other chemoattractants. Invasive cells were
determined as described in Materials and methods. The data are presented as a mean ± standard deviation of 4 independent studies. “*” p< 0.001
(Student’s T-test).
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Background: High risk of recurrence/progression bladder tumours is treated with Bacillus Calmette-Gue´rin (BCG) immunotherapy
after complete resection of the tumour. Approximately 75% of these tumours express the uncommon carbohydrate antigen sialyl-Tn
(Tn), a surrogate biomarker of tumour aggressiveness. Such changes in the glycosylation of cell-surface proteins influence
tumour microenvironment and immune responses that may modulate treatment outcome and the course of disease. The aim
of this work is to determine the efficiency of BCG immunotherapy against tumours expressing sTn and sTn-related antigen
sialyl-6-T (s6T).
Methods: In a retrospective design, 94 tumours from patients treated with BCG were screened for sTn and s6T expression. In vitro
studies were conducted to determine the interaction of BCG with high-grade bladder cancer cell line overexpressing sTn.
Results: From the 94 cases evaluated, 36 had recurrence after BCG treatment (38.3%). Treatment outcome was influenced by age
over 65 years (HR¼ 2.668; (1.344–5.254); P¼ 0.005), maintenance schedule (HR¼ 0.480; (0.246–0.936); P¼ 0.031) and multifocallity
(HR¼ 2.065; (1.033–4.126); P¼ 0.040). sTn or s6T expression was associated with BCG response (P¼ 0.024; Po0.0001) and with
increased recurrence-free survival (P¼ 0.001). Multivariate analyses showed that sTn and/or s6T were independent predictive
markers of recurrence after BCG immunotherapy (HR¼ 0.296; (0.148–0.594); P¼ 0.001). In vitro studies demonstrated higher
adhesion and internalisation of the bacillus to cells expressing sTn, promoting cell death.
Conclusion: s6T is described for the first time in bladder tumours. Our data strongly suggest that BCG immunotherapy is efficient
against sTn- and s6T-positive tumours. Furthermore, sTn and s6T expression are independent predictive markers of BCG
treatment response and may be useful in the identification of patients who could benefit more from this immunotherapy.
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Bladder cancer is the fifth most common cancer in Western society
(van Rhijn et al, 2009), with the highest recurrence rate among
solid tumours and poor prognosis when the tumour invades the
muscularis propia (Babjuk et al, 2011). To reduce the risk of
recurrence and progression to muscle invasion, non-muscle
invasive high-grade tumours, multifocal and recurrent lesions are
submitted to intravesical instillations with live attenuated Bacillus
Calmette-Gue´rin (BCG) after complete transurethral resection of
bladder tumour (TURBT; Babjuk et al, 2011). Although the
management of the disease has significantly improved with this
therapeutics, 30–40% of the patients relapse and approximately
15% progress to muscle invasive tumours (Palou Redorta, 2006).
Predicting patients who could be best served by an alternative
treatment or early cystectomy, would avoid progression, reduce
disease charge and decrease health expenses. It is consensual that
the integration of multiple biomarkers may hold predictive value;
still such biomarker panel remains to be established (Lima et al,
2012; Zuiverloon et al, 2012).
The exact mechanism by which BCG mediates anti-bladder
cancer immunity remains elusive (Alexandroff et al, 2010).
However, the capability of the bacillus to recognise and efficiently
bind to tumour cells has a determinant role in the therapeutics
outcome (Alexandroff et al, 2010). The bacillus is then internalised
triggering tumour cell apoptosis or host adaptive immune
responses (Becich et al, 1991; Ratliff, 1992). The bacterial adhesion,
fibronectin attachment protein (FAP), was recognised as the main
factor mediating BCG attachment and internalisation by bladder
tumour cells (Sinn et al, 2008; Alexandroff et al, 2010). FAP binds
to a5b1 integrins expressed by tumour cells via a fibronectin bridge
and to be responsible for the uptake of BCG–fibronectin–integrin
complexes (Sinn et al, 2008; Alexandroff et al, 2010).
Malignant transformations may be accompanied by a premature
stop in the O-glycosylation of proteins by sialylation, originating
the sialyl-Tn (sTn, Neu5Aca2-6GalNAca-O-Ser/Thr) and sialyl-
6-T antigens (s6T, Galb1-3(Neu5Aca2-6)GalNAca-O-Ser/Thr;
Dall’Olio et al, 2012). We recently reported that approximately
75% of high-grade bladder tumours, presenting elevated prolifera-
tion indexes and high risk of recurrence/progression expressed sTn
(Ferreira et al, 2013). sTn expression enhanced the invasive
capability of bladder cancer cells and was considered a surrogate
biomarker of tumour aggressiveness (Ferreira et al, 2013). Hence,
efficient therapies to manage these tumours are needed to avoid
disease progression and poor outcomes.
sTn expression is known to interfere with cell–cell adhesion,
cell–matrix interaction, including integrin-fibronectin binding,
modulate cell morphology (Clement et al, 2004; Julien et al,
2006; Pinho et al, 2007) and immune responses (Gilewski et al,
2007; Julien et al, 2009; Takamiya et al, 2013). Thus, we
hypothesise it may modulate BCG attachment to tumour cells
and/or immune response and consequently influence BCG
immunotherapy outcome. sTn is also a biomarker of concomitant
molecular alterations that may further determine the tumour
behaviour (Ohno et al, 2006). As such, this work is devoted to
evaluating the response of sTn-positive bladder tumours to BCG
immunotherapy. The sTn structurally related antigen was also
evaluated for the first time in the context of bladder cancer.
MATERIALS AND METHODS
Patient cohort. This study was performed in a retrospective series
of 94 cases with high-risk non-muscle invasive bladder cancer.
Patients were treated with TURBT and then submitted to BCG
immunotherapy in the Portuguese Oncology Institute of Porto,
between 1998 and 2006. No second-look TURBT was performed,
although the majority of the samples had muscularis propria
tumour free. All received intravesical instillation of BCG for 6
consecutive weeks (induction BCG scheme, iBCG) and 56.4% were
submitted to maintenance BCG schedule (iBCGþmaintenance
protocol with two weekly instillations every 3 months during 2
years, mBCG). The iBCG group includes patients treated before the
European Association of Urology guidelines recommending the
mBCG (Oosterlinck et al, 2006) scheme and patients showing
significant intolerance to long BCG treatment.
The male/female sex ratio was of 78:16. The patients were
followed every 3 months for the first year, every 6 months for the
second year and every 12 months thereafter by cystoscopy and
urine cytology. Recurrence was defined as the appearance of a
tumour once the treatment has begun, with at least one tumour-
free cystoscopy and cytology in-between. These recurrences were
also available for study. The non-responders were defined as
patients submitted to BCG treatment with tumour recurrence.
Finally, recurrence-free survival (RFS) was defined as the period of
time between the beginning of treatment and recurrence or the
most recent tumour-free cystoscopy and cytology. All procedures
were performed after patient’s informed consent and approved
by the Ethics Committee of IPO-Porto. All clinicopathological
information was obtained from patients’ clinical records. All
tumour samples were revised by a pathologist, regarding 2004
WHO grading criteria.
Expression of STn in bladder tumours. Formalin-fixed paraffin-
embedded tissue sections were screened for sTn by immunohisto-
chemistry using the avidin/biotin peroxidase method, as described by
Ferreira et al (2013). sTn expression was evaluated with anti-sTn
mouse monoclonal antibody clone TKH2 (Ferreira et al, 2013). The
s6T antigen was evaluated in sTn-negative tumours using the same
antibody, after treatment with a recombinant b-(1-3)-galactosidase
from Xanthomonas campestris (R&D systems, Minneapollis, MN,
USA) for 1h at 371C. This enzyme removes the O-3-linked Gal
residues exposing the sTn antigen (Figure 1A).
Both antigens were assessed double-blindly by three indepen-
dent observers. Upon disagreement, the slides were reviewed, until
a consensus was reached. Tumours were classified as positive when
immunoreactivity of anti-sTn TKH2 antibody was observed.
Structural assignments were validated by a combination of
enzymatic treatments. For sTn, positive tissues were first treated
with a a-neuraminidase from Clostridium perfringens (Sigma-
Aldrich, St Louis, MO, USA) for 2 h at 37 1C to remove the sialic
acid and then screened for sTn expression. For s6T, positive tissues
were primarily incubated with the b-(1–3)-galactosidase, followed
by incubation with the neuraminidase. The absence or decrease in
immunoreactivity of TKH2 monoclonal antibody confirmed the
presence of these structures.
Adhesion and internalisation of BCG to bladder cancer cell line
Cell lines culture. The human bladder cancer cell line MCR and
the transduced variants of MCR (MCRnc and MCRsTnþ ) were
grown as described by Videira et al (2009). The MCRsTnþ cell line
results from the stable transduction of MCR cells with a lentivirus
expressing the coding region of the human ST6GalNAc.I gene, the
enzyme responsible by the biosynthesis of sTn (Ferreira et al,
2013). The MCRnc cell line, not expressing sTn, was used as
control (Ferreira et al, 2013).
Bacterial strain and labelling. BCG strain RIVM (Medac,
Hamburg, Germany) was used in this study. Briefly, 108 viable
BCG cells were labelled with 10mg fluorescein isothiocyanate (FITC;
Invitrogen, Carlsbad, CA, USA) in 1ml of 50mM sodium carbonate
buffer (pH 9.2) for 30min at 20 1C. The labelled bacteria (BCG-FITC)
were washed three times with PBS containing 0.05% of Tween-80
(Sigma-Aldrich) and centrifuged for 10min at 13.000 g to remove
excess FITC.
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BCG adhesion and internalisation assay. MCR cells were
plated into 24-well plates at 0.2 106 cell per well. At
confluence, cells were washed and BCG-FTIC was added to
the cultures at a ratio of 10:1 (BCG/cells). After 2, 6 or 24 h
incubation time, the cells were gently washed to remove the
excess BCG, harvested and centrifuged at 350 g for 5 min. In
order to differentiate between internalised and surface-bound
BCG, trypan blue was added to quench surface-attached
fluorescence bacteria. Flow cytometry was performed on a
FACSCalibur (BD Biosciences, San Jose, CA, USA) and data
were analysed using the Flowing v2.4 software (Turku Center for
Biotechnology, Turku, Finland).
Estimation of cell viability after exposure to BCG. The influence
of BCG treatment on MCR cell viability after the 24 h of exposure
was assessed through the visualisation of morphologic changes by
flow cytometry. Dot plots of forward-angle light scatter (FSc) vs
side-angle light scatter (SSc) of MCR cells before and after
exposure to BCG were analysed using the Flowing v2.4 software
(Turku Center for Biotechnology).
For a shorter period of time of BCG exposure (6 h), apoptotic
status of cells was evaluated by labelling with Annexin V (Sigma-
Aldrich) as indicated by manufacture instructions.
Statistical analysis. Statistical data analysis was performed with IBM
Statistical Package for Social Sciences—SPSS for Windows (version
20.0; IBM, Armonk, NY, USA). Chi-square analysis was used to
compare categorical variables. Kaplan–Meier survival curves were
used to evaluate correlation between glycans expression and RFS, log-
rank statistical test was used for curves comparison. Multiple Cox
regression analysis was used to assess the effect of both antigens on
the time to recurrence in BCG-treated patients and to adjust for
potential confounders. Non-parametric Mann–Whitney test was used
to compare the differences in the BCG attachment and internalisation
to MCRnc and MCRsTnþ cells.
RESULTS
Clinicopathological features and BCG treatment outcome.
From the 94 cases evaluated, 36 had recurrence after BCG
GalNAc STn (Neu5Ac2–6GalNAc-O-Ser/Thr) 
S6T (Gal1-3(Neu5Ac2–6)GalNAc-O-Ser/Thr)
Urothelial cellAnti-STn MoAb TKH2
STn–
TKH2 TKH2 TKH2 + -(1–3)-galactosidase
-(1–3)-galactosidase
STn+ S6T+
Tumour cell
Gal
Neu5Ac (sialic acid)
1 2
Figure 1. Expression of sTn and s6T in bladder tumours. Schematic representation of a bladder tumour expressing sTn and s6T antigens (A).
Urothelial cell-surface glycoproteins present more or less elongated O-glycan chains often terminated with ABO and/or Lewis blood group
determinants (not represented). Conversely, some malignant cells express the sTn and s6T (STnþGal residue) antigens that result from a
premature stop in the biosynthesis of O-glycans (A). The sTn, but not the s6T antigen, can be recognised by mouse monoclonal antibody TKH2
(A1). The digestion of the FFPE sections with a b-(1-3)-galactosidase removes the Gal residue from s6T allowing detection by TKH2 (A2). Bladder
tumour expressing the sTn antigen (B). Bladder tumour expressing the s6T antigen but not sTn (C). The FFPE tissue was positive for sTn only after
digestion of the FFPE tissue with a b-(1-3)-galactosidase. This is the first report on s6T antigen expression in bladder tumours.
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treatment (38.3%). The median follow-up time of the patients free
of recurrence was 68.5 months (range: 6.0–135.0) and the median
time of recurrence was 38.5 months (range: 10.0–122.0). The
median follow-up time considering all the cases under analysis was
61.0 months (range: 6.0–135.0). Table 1 summarises patients and
tumour clinicopathological features and its association with BCG
response and RFS after treatment. We found that 61.1% of the non-
responders were over 65 years old at the time of tumour resection,
whereas only 36.2% of responders were over 65 years old (P¼ 0.018).
Furthermore, patients over 65 years have approximately three-fold
increased risk of recurrence (HR¼ 2.668; (1.344–5.254); P¼ 0.005).
Moreover, it was observed a higher percentage of patients treated only
with iBCG in the non-responder group when compared with the
responder group (58.3% vs 34.5%, P¼ 0.018). Therefore, patients
treated with mBCG scheme showed a 52% reduced risk of recurrence
(HR¼ 0.480; (0.246–0.936); P¼ 0.031). It was also found that patients
with multifocal tumours had an increased risk of recurrence after
BCG treatment (HR¼ 2.065; (1.033–4.126); P¼ 0.040). No associa-
tion was found for other characteristics, such as gender, tumour stage,
grade or size, CIS presence and prior recurrence.
Expression of sTn and s6T and association with clinicopatho-
logical features. Approximately 66% of the studied bladder
tumours were sTn positive (Figure 1A and B) and in all cases
the antigen was observed in more than 5% of the tumour area.
Additionally, 10 out of 32 sTn negative cases were positive for s6T
(Figure 1C), which is structurally related to sTn. However, s6T
assumed a more diffuse expression that did not exceed 5% of the
tumour area in all cases.
The expression of sTn alone or in combination with s6T (sTn/s6T)
was associated with high-grade tumours (P¼ 0.007; P¼ 0.037
Table 2) and also with primary tumours (P¼ 0.001; P¼ 0.039).
STn and sTn/s6T as predictors of BCG treatment outcome. sTn
antigen was expressed by 74.1% of BCG responders and only by
47.2% of non-responders (P¼ 0.034; Table 3). When sTn and s6T
were evaluated together, a similar relationship was observed
(P¼ 0.0001; Table 3).
From the 94 patients included in this study, 36 had recurrences
after treatment and 75% of these tumour specimens were available
for sTn and s6T screening. All non-responders who presented sTn-
Table 1. Relation between patients clinical and tumour characteristics and response to BCG treatment and time to recurrence
Variables Total n (%) Responders n (%) Non-responders n (%) Pa HR (95% CI) Pb
Age (years)
o65 51 (54.3) 37 (63.8) 14 (38.9) 0.018 1.0
X65 43 (45.7) 21 (36.2) 22 (61.1) 2.668 (1.355–5.254) 0.005
Sex
Male 78 (83.0) 47 (81.0) 31 (86.1) 0.524 1.0
Female 16 (17.0) 11 (19.0) 5 (13.9) 0.883 (0.342–2.283) 0.798
Stage
Ta 40 (42.6) 23 (39.7) 17 (47.2) 0.471 1.0
T1 54 (57.4) 35 (60.3) 19 (52.8) 0.838 (0.435–1.613) 0.596
Grade
Low 38 (40.4) 24 (41.4) 14 (38.9) 0.843 1.0
High 56 (59.6) 34 (58.6) 22 (61.1) 1.295 (0.661–2.537) 0.450
Size (cm)
o3 62 (66.7) 38 (65.5) 24 (68.6) 0.762 1.0
X3 31(33.3) 20 (34.5) 11 (31.4) 0.787 (0.384–1.613) 0.513
Tumour number
Unifocal 51 (54.3) 30 (51.7) 13 (36.1) 0.140 1.0
Multifocal 43 (45.7) 28 (48.3) 23 (63.9) 2.065 (1.033–4.126) 0.040
CIS
No 88 (93.6) 54 (93.1) 34 (94.4) 1.000 1.0
Yes 6 (6.4) 4 (6.9) 2 (5.6) 0.783 (0.188–3.267) 0.737
Recurrence status
Primary 48 (51.0) 31 (53.4) 17 (47.2) 0.557 1.0
Recurrent 46 (49) 27 (46.6) 19 (52.8) 1.327 (0.686–2.564) 0.401
BCG schedule
iBCG 41 (43.6) 20 (34.5) 21 (58.3) 0.023 1.0
mBCG 53 (56.4) 38 (65.5) 15 (41.7) 0480 (0.246–0.936) 0.031
Abbreviations: BCG¼Bacillus Calmette-Gue´rin; CI¼ confidence interval; CIS¼Carcinoma in situ; HR¼ hazard ratio; iBCG¼ induction BCG; mBCG¼maintenance BCG.
Bold values indicate Po0.05.
a
Chi-square test.
b
Wald test.
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negative tumours prior treatment had sTn-negative recurrences.
From the 15 non-responder patients who had sTn-positive
tumours, 40% presented sTn-negative recurrences.
Kaplan–Meier analysis was used to evaluate if sTn with or
without s6T influenced the RFS after BCG treatment. No
differences were found regarding sTn expression alone
(Figure 2A). However, when sTn and s6T were considered
together, significant differences were found (P¼ 0.001;
Figure 2B). Patients with sTn/s6T-positive tumours had higher
RFS than negative tumours (100.1 vs 63.2 months).
A Cox regression analysis, adjusted to age, tumour number and
treatment scheme, was performed to assess the individual effect of
these antigens in recurrence after BCG. Patients with sTn-positive
tumours presented a trend to a lower-risk recurrence after BCG
(HR¼ 0.544; 95% CI: (0.275–1.076); P¼ 0.080; Table 4). Likewise,
cases positive for sTn/S6T showed a significant lower risk of
recurrence (HR¼ 0.296; 95% CI: (0.148–0.594); P¼ 0.001).
BCG interaction with MCRsTnþ cell line. To evaluate the
affinity of BCG for cells expressing sTn, we set up in vitro assays
with MCRnc and MCRsTnþ cell lines, two genetically modified
variants of the original MCR bladder cancer cell line. MCRnc cells
Table 2. Association between sTn and s6T antigens and clinicopathological characteristics
sTn sTnþ s6T
Variables Negative n (%) Positive n (%) Pa Negative n (%) Positive n (%) Pa
Age (years)
o65 21 (65.6) 30 (48.4) 0.112 13 (59.1) 38 (52.8) 0.603
X65 11 (34.4) 32 (51.6) 9 (40.9) 34 (47.2)
Sex
Male 27 (84.4) 51 (86.1) 0.796 17 (77.3) 61 (84.7) 0.517
Female 5 (15.6) 11 (17.7) 5 (22.7) 11 (15.3)
Stage
Ta 16 (50.0) 24 (38.7) 0.294 10 (45.5) 30 (41.7) 0.753
T1 16 (50.0) 38 (61.3) 12 (54.5) 42 (58.3)
Grade
Low 19 (59.4) 19 (30.6) 0.007 13 (59.1) 25 (34.7) 0.042
High 13 (40.6) 43 (69.4) 9 (40.9) 47 (65.3)
Size (cm)
o3 23 (74.2) 39 (62.9) 0.276 16 (76.2) 46 (63.9) 0.431
X3 8 (25.8) 23 (37.1) 5 (23.8) 26 (36.1)
Tumour number
Unifocal 12 (37.5) 13 (50.0) 0.249 7 (31.8) 36 (50.0) 0.134
Multifocal 20 (62.5) 31 (50.0) 15 (68.2) 36 (50.0)
CIS
No 29 (90.6) 59 (95.2) 0.406 19 (86.4) 69 (95.4) 0.112
Yes 3 (9.4) 3 (4.8) 3 (13.6) 3 (4.2)
Recurrence status
Primary 9 (28.1) 39 (62.9) 0.001 7 (31.8) 41 (56.9) 0.039
Recurrent 23 (71.9) 19 (37.1) 15 (68.2) 31 (43.1)
BCG schedule
iBCG 14 (43.8) 27 (43.5) 0.985 11 (50.0) 30 (41.7) 0.490
mBCG 18 (56.2) 35 (56.5) 11 (50.0) 42 (58.3)
Abbreviations: BCG¼Bacillus Calmette-Gue´rin; iBCG¼ induction BCG; CIS¼Carcinoma in situ; mBCG¼maintenance BCG.
Bold values indicate Po0.05.
a
Chi-square test.
Table 3. STn and sTn/s6T frequencies and risk of recurrence after BCG
therapy
Responders n (%) Non-responders n (%) P valuea
sTn
Negative 15 (25.9) 17 (47.2)
Positive 43 (74.1) 19 (52.8) 0.034
sTn and/or s6T
Negative 6 (10.5) 16 (43.2)
Positive 51 (89.5) 21 (56.8) 0.0001
Abbreviation: BCG¼Bacillus Calmette-Gue´rin.
a
Chi-square test.
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were transduced with an empty vector and MCRsTnþ with the
cDNA coding for the ST6GalNAc.I sialyltransferase. The pheno-
type of these transduced variants was previously described by
Ferreira et al (2013). MCRsTnþ presents a continuous and stable
expression of the antigen sTn, whereas the MCRnc does not as
shown in Supplementary Figure 1 (in the supplementary section).
MCRsTnþ and its negative control MCRnc where then treated
with BCG. Fluorescent-labelled BCG was internalised significantly
over time, with a significant higher internalisation after 6 h incubation,
when comparing with 2h incubation (Figure 3A). Interestingly, after
6 h, MCRsTnþ cells showed a tendency to internalise higher amounts
of BCG than MCRnc cells (Figure 4A and B). Small amounts of BCG
are internalised, resulting in small shifts of FITC fluorescence of the
cells after internalisation (Figure 4B).
We then evaluated apoptosis status in MCR cells after 6 h of
BCG challenging, using Annexin V an earlier labelling marker for
cells undergoing apoptosis. It was observed a consistent tendency
for a higher cell death in MCRsTnþ after BCG challenging (higher
Annexin V labelling—MFIMCRnc¼ 2560) compared with MCRnc
cells (MFIMCRsTnþ ¼ 2640). In addition, a population of cells
presenting stronger Annexin V labelling was also observed after 6 h
BCG, which was higher (7%) in MCRsTnþ cell than MCRnc (4%;
Figure 4A). After a longer period of BCG challenging (24 h),
MCRsTnþ cells significantly decreased their size and granularity
(80% of FSClowSSClow), which is usually typical of a rupture of
plasma membrane and leakage of the cell’s contents (Figure 4B).
Conversely, MCRnc cells underwent little physical changes,
presenting only 10% of FSClowSSClow (Figure 4B). Furthermore,
the internalisation of BCG by viable MCRsTnþ cells at 24 h was
markedly increased in relation to the controls (MCRnc;
Supplementary Figure 2, supplementary section), therefore, in
accordance with the observations made for 6 h.
These results present evidence that both BCG internalisation
and loss of cell viability are correlated and both features are
enhanced in cells expressing sTn antigen. Altogether, these
findings suggest that the bacillus acts more efficiently in cells
expressing sTn probably due to its higher internalisation.
DISCUSSION
A significant percentage of high risk of recurrence/progression
bladder tumours, conservatively treated with BCG immunotherapy
after surgery, express cell-proteins yielding the sTn antigen
(Ferreira et al, 2013). Despite the malignant potential of these
tumours (Ferreira et al, 2013) and evidences that sTn expression
may modulate the cell–BCG interaction (Clement et al, 2004;
Julien et al, 2006; Pinho et al, 2007) as well as immune responses
(Gilewski et al, 2007; Julien et al, 2009; Takamiya et al, 2013),
nothing is known about the way patients exhibiting sTn-positive
tumours respond to treatment.
We first observed that treatment outcome was influenced
by age, treatment scheme and tumour multifocallity, as showed
in other reports (Bohle and Bock, 2004; Joudi et al, 2006;
Fernandez-Gomez et al, 2008; Malmstrom et al, 2009; Kohjimoto
et al, 2010; Ajili et al, 2012). To overcome the samples
heterogeneity, these variables were taken into account in multi-
variate analysis models to assess the influence of tumour-associated
glycans in BCG response.
We also found that sTn expression was associated with high-
grade tumours, which is in agreement with our previous
observations (Ferreira et al, 2013). STn expression was also
associated with primary tumours. However, this may result from
fact that the percentage of high-grade tumours was much higher
among primary cases (90%) than in recurrences (67%). Altogether,
these data reinforce the notion that sTn is a surrogate marker of
high-risk bladder cancer.
Furthermore, we report for the first time that bladder
tumours express the sTn-related carbohydrate antigen s6T.
From the structural point of view, s6T may be considered a form
of the sTn antigen masked by a Gal residue O-3 linked to the
GalNAc moiety. To our knowledge, s6T has only been observed
in human cancer cell lines (Marcos et al, 2004; Julien et al, 2006;
Pinho et al, 2007). We also describe that the incubation of tissue
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Figure 2. Effect of sTn and s6T expression in recurrence-free survival (RFS). Kaplan–Meier analysis to evaluate the association between RFS in the
studied patients and: (A) sTn expression; (B) STn plus s6T presence (sTn/S6T). Comparison performed by log-rank test (A: P¼ 0.157; B: P¼ 0.001);
± censored sTn or sTn/s6T-negative tumours; ~ censored sTn or sTn/s6T-negative tumours.
Table 4.Multivariate analysis and risk estimation of sTn and s6T influence
on BCG therapy outcome
HRa 95% CI P value
sTn
Negative 1.0 Referent
Positive 0544 0275–1.076 0.080
sTnþ s6T
Negative 1.0 Referent
Positive 0296 0148–0.594 0.001
Abbreviations: BCG¼Bacillus Calmette-Gue´rin; CI¼ confidence interval; HR¼ hazard ratio.
a
Adjusted for age, tumour number and BCG schedule.
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sections with a b-(1-3)-galactosidase removed the O-3-linked
Gal residue exposing the sTn antigen, allowing its detection by
immunohistochemistry with the same antibody used for sTn
without significant time consumption. This approach may now
be applied to estimate s6T expression in other solid tumours.
Studies in vitro studies have shown that s6T expression
influences tumour microenvironment similarly to sTn (Pinho
et al, 2007). Therefore, both antigens were evaluated in the
context of BCG immune response.
STn expression alone or in combination with that of s6T was
associated with lower recurrence rates after BCG. Furthermore,
patients expressing sTn and/or s6T presented longer RFS and these
antigens were found to be independent predictive markers of
reduced recurrence after BCG immunotherapy. Moreover, recur-
rences after treatment displayed a reduced expression of sTn
antigens suggesting that BCG may be more effective against cells
expressing these glycans. Thus, sTn-like O-glycans should be
considered in a biomarker panel directed to predict BCG treatment
outcome.
STn-expressing cells presented enhanced capacity for BCG
adhesion and internalisation and higher BCG-mediated cell death
in vitro. This strongly suggests that sTn expression favours BCG-
mediated elimination of tumour cells, which may, in part, explain
the high correlation between these glycans and treatment response.
The exact mechanism underlying these observations remains
unknown. However, BCG is known to bind fibronectin–a5b1
integrin complexes promoting a rearrangement of cytoskeletal
actin in host cells, which results in the phagocytosis of the
pathogen (Chen et al, 2003; Alexandroff et al, 2010). Clement et al
(2004) described that integrin b1 chains express sTn and that the
antigen enhanced integrin-fibronectin adhesion. Thus, sTn may
contribute to a more efficient binding of the bacillus to tumour
cells and consequently a better response to BCG. The bacillus may
also directly target cells in a fibronectin-independent manner
(Schneider et al, 1994), namely by binding sTn or specific
carbohydrates residues such as a2,6 sialic acids. On the other
hand, sTn is a product of incomplete O-glycosylation of proteins
(Dall’Olio et al, 2012), a reduction in the structural complexity of
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Figure 4. Effect of BCG in the viability of bladder cancer cell lines expressing sTn. (A) The apoptotic status of MCR cell lines was evaluated after
6 h exposure to BCG, by Annexin V staining and flow cytometry analysis. Flow cytometry histograms show MCRnc and MCRsTnþ cells labelled
with Annexin V before (light grey histograms) and after 6 h of BCG treatment (dark grey and open histograms, respectively). MCRsTnþ cells
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Annexin V labelling (4% to 7%—vertical arrow). (B) Analysis of size and granularity of cells exposed 24 h to BCG. Dot plot analysis of BCG-treated
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O-glycan may allow the bacillus to bind more efficiently to tumour
cells. The expression of sTn also induces profound morphological
changes in tumour cells (Clement et al, 2004; Pinho et al, 2007)
that may further contribute to the bacillus attachment. A deeper
understanding of these phenomena may provide new insights on
the mechanism of action of BCG and ways to improve the
therapeutics.
The efficiency of BCG therapy among sTn-positive tumours
may also be related with the immunogenic properties of the
antigen (Gilewski et al, 2007; Julien et al, 2009; Takamiya et al,
2013). sTn-based vaccines elicit strong immune responses against
breast, ovarian and colorectal cancers in animal models (Gilewski
et al, 2007; Julien et al, 2009). Still, using BCG as an immunologic
adjuvant was considered essential for the development of both
humoral and cellular immune responses against sTn (Miles et al,
1996; O’Boyle et al, 2006). Similarly, instillations with BCG may be
enhancing immune responses against these tumour-associated
glycans. On the other hand, we observed a higher internalisation of
BCG by sTn-expressing cells. After BCG internalisation, malignant
cells often act as antigen-presenting cells contributing to the
immunologic cascade that leads to tumour clearance (Ratliff, 1992;
Alexandroff et al, 2010). Therefore, one may also hypothesise that
the expression of this particular glycan may increase the
probability of generating BCG antigen-presenting cells in the
tumour niche. Understanding these events may allow developing
alternative carbohydrate-based immunotherapies for bladder
cancer and should be addressed in future studies.
Although this is a retrospective study involving a limited
number of cases, our results strongly suggest that BCG
immunotherapy is efficient against sTn-positive tumours. Even
though we have not determined the exact mechanisms underlying
this event, we demonstrated that BCG adhesion and internalisation
is higher for sTn-positive cells in vitro, further reinforcing tumour
findings.
In conclusion, it has been demonstrated that sTn and s6T
antigens correlated with a better response to this treatment. These
glycans, in association with other BCG response-associated
molecules, may allow the establishment of a predictive panel that
can guide therapeutic decision.
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Abstract
Muscle invasive bladder cancer (MIBC, stageT2) is generally associated with poor prog-
nosis, constituting the second most common cause of death among genitourinary tumours.
Due to high molecular heterogeneity significant variations in the natural history and disease
outcome have been observed. This has also delayed the introduction of personalized thera-
peutics, making advanced stage bladder cancer almost an orphan disease in terms of treat-
ment. Altered protein glycosylation translated by the expression of the sialyl-Tn antigen
(STn) and its precursor Tn as well as the activation of the PI3K/Akt/mTOR pathway are can-
cer-associated events that may hold potential for patient stratification and guided therapy.
Therefore, a retrospective design, 96 bladder tumours of different stages (Ta, T1-T4) was
screened for STn and phosphorylated forms of Akt (pAkt), mTOR (pmTOR), S6 (pS6) and
PTEN, related with the activation of the PI3K/Akt/mTOR pathway. In our series the expres-
sion of Tn was residual and was not linked to stage or outcome, while STn was statically
higher in MIBC when compared to non-muscle invasive tumours (p = 0.001) and associated
decreased cancer-specific survival (log rank p = 0.024). Conversely, PI3K/Akt/mTOR path-
way intermediates showed an equal distribution between non-muscle invasive bladder can-
cer (NMIBC) and MIBC and did not associate with cancer-specif survival (CSS) in any of
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these groups. However, the overexpression of pAKT, pmTOR and/or pS6 allowed discrimi-
nating STn-positive advanced stage bladder tumours facing worst CSS (p = 0.027). Further-
more, multivariate Cox regression analysis revealed that overexpression of PI3K/Akt/
mTOR pathway proteins in STn+ MIBC was independently associated with approximately
6-fold risk of death by cancer (p = 0.039). Mice bearing advanced stage chemically-induced
bladder tumours mimicking the histological and molecular nature of human tumours were
then administrated with mTOR-pathway inhibitor sirolimus (rapamycin). This decreased the
number of invasive lesions and, concomitantly, the expression of STn and also pS6, the
downstream effector of the PI3K/Akt/mTOR pathway. In conclusion, STn was found to be
marker of poor prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR path-
way evaluation, holds potential to improve the stratification of stage disease. Animal experi-
ments suggest that mTOR pathway inhibition could be a potential therapeutic approach for
this specific subtype of MIBC.
Introduction
Bladder cancer is the second most deadly genitourinary tumour and presents significantly
worse prognosis uponmuscularis propria invasion [1]. Approximately 20–30% of the newly
diagnosed cases are muscle invasive bladder cancers (MIBC; T2-T4 stages), while 50% are non-
muscle invasive bladder tumours (NMIBC) with high potential to progress to invasion. MIBC
treatment includes cystectomy and (neo)adjuvant cisplatin-based chemotherapy regimens [2].
However, significant variations in the natural history of the disease and responses to treatment
can be observed between tumours with identical histological features, reflecting their high
molecular heterogeneity [3]. Furthermore, approximately 50% of cases develop metastasis
within 5 years, urging the identification of biomarkers to assist prognostication and the devel-
opment of more effective targeted therapeutics [4].
To meet this need, we have recently addressed the expression of the cancer-associated sia-
lyl-Tn antigen (STn) on a small prospective series of unselected bladder cancer patients [5].
STn is an abnormal post-translational modification that results from a premature stop in cell-
membrane proteins O-glycosylation by sialylation of the Tn antigen (Fig 1A). In bladder
tumours, STn it was mainly present in advanced stage cases, while absent from most low-grade
NMIBC [5]. Moreover, it was not expressed by the normal urothelium, denoting a cancer-spe-
cific nature [5]. Studies in vitro showed that STn expression endowed bladder cancer cells with
high invasion capability [5] and an immunotolerogenic phenotype, potentially favoring disease
dissemination [6]. Alterations in cell-surface protein glycosylation have be implicated in the
activation of intracellular oncogenic signalling pathways [7], including the phosphoinositide-3
kinase (PI3K)/Akt signalling pathway [8] which is thought to play a critical role in bladder can-
cer development. These preliminary observations support the hypothesis that STn expression
may play a key role in disease outcome, which warrants a deeper investigation. Several studies
also suggest that Tn antigen, which is a precursor of STn, may be also implicated in oncogenic
events [7]; however nothing is known about the expression of this glycan in bladder tumours.
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) pathways are interconnected signaling cascades essential for bladder cell growth and
survival (Fig 1B). The PI3K/Akt/mTOR or mTOR pathway integrates a multiplicity of extracel-
lular signals to regulate downstream signaling and protein synthesis, which ultimately leads to
Glycosylation and PI3K/Akt/mTOR Pathway in Bladder Cancer
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Fig 1. Schematic representation of membrane proteinO-glycosylation and the PI3K/Akt/mTOR pathways. A) Representation of membrane proteinO-
glycosylation with emphasis on the STn expression by cancer cells. This is a highly regulated process of critical importance for protein stability and function.
Briefly, newly synthesized proteins areO-glycosylated in the Golgi apparatus by the ppGalNAcTs-mediated addition of GalNAc moiety to Ser/Thr residues.
This originates the Tn antigen (GalNAc-O-Ser/Thr-protein backbone), which is the simplest O-glycan. In normal cells these chains are extended through the
sequential addition of other sugars first by CGALT-1 and then other enzymes. This culminates in highly complex, heterogeneous and elongated glycans
often terminated by ABO or Lewis blood group related antigens (left drawing). In cancer cells the Tn antigen is immediately sialylated by ST6GalNAc.I,
originating the STn antigen (Neu5Ac-GalNAc-O-Ser/Thr-protein backbone), thereby inhibiting further chain elongation (right drawing). The expression of STn
at the cell surface influences cell-cell adhesion and cancer cell recognition, favouring motility, invasion and immune escape. B) Schematic representation of
the PI3K/Akt/mTOR pathway, which is ubiquitously activated in bladder tumours. This is a highly conserved pathway regulated mainly by a wide variety of
extracellular signals, including mitogenic growth factors, hormones, nutrients, cellular energy levels, and stress conditions. These signals activate tyrosine
receptor kinases that recruit PI3K, which catalyses the conversion of membrane-bound PIP2 to PIP3. Then Akt and PDK-1 are activated through binding to
PIP3. PTEN preferentially dephosphorylates PIP3, inhibiting signalling progression. Full Akt activation requires double phosphorylation by PDK-1 itself and
PDK-2 (not shown). Akt phosphorylates mTOR directly or may also inactivate TSC1/TSC2 complex, inhibiting mTOR inactivation. mTORC1 triggers cell
growth and proliferation by phosphorylating eukaryotic translation regulators, among these p70S6 kinase (p70S6K or S6K1) that, in turn, phosphorylates the
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a competitive growth advantage, metastatic competence, angiogenesis, and therapy resistance
[9]. The signaling cascade begins with PI3K activation in the cell membrane followed by ser-
ine/threonine kinase Akt cell membrane translocation and activation. The best studied down-
stream substrate of Akt is the serine/threonine kinase mTOR, whose downstream effector is S6
kinase-1 (S6K1). In particular, a subset of mTOR pathway alterations have been shown to
occur in bladder cancer, such as mutations in PIK3CA gene, which culminates with increased
mTOR signaling and bladder cancer cells resistance to apoptosis [10]. Moreover, the pharma-
cological or biochemical inhibition of the PI3K pathway drastically reduced the invasive capac-
ity of bladder cancer cell lines. Furthermore, over half of primary human bladder tumours
present high Akt phosphorylation and the aberrant activation of this pathway has been sug-
gested to contribute to invasion [11]. Another event influencing mTOR pathway activation in
bladder tumours involves the loss of tumor suppressor PTEN (phosphatase and tensin homo-
log deleted on chromosome ten) function [12]. PTEN normally suppresses activation of the
PI3K/Akt/mTOR pathway antagonizing PI3K and preventing activation of Akt and PDK-1.
PTEN also functions to regulate chemotaxis and cell motility, thereby promoting tumor inva-
sion [13]. In summary, there are evidences that a comprehensive evaluation of PI3K/Akt/
mTOR pathway associated proteins may hold significant potential for value for patient stratifi-
cation. Moreover, many preclinical and clinical studies support that mTOR inhibitors, such as
sirolimus (rapamycin) and their derivatives may improve cancer treatment [13,14].
Based on these observations we hypothesize that Tn and/or STn may act synergistically with
the mTOR pathway to drive bladder cancer progression. As such, we have devoted to evaluat-
ing the expression of STn and proteins associated with the activation of the PI3K/Akt/mTOR
pathway activation in bladder tumours at different stages. We anticipate that the combination
of extracellular and intracellular oncogenic events may improve patient stratification and pro-
vide insights for novel therapeutics. Furthermore we have estimated the impact of sirolimus in
chemically-induced urothelial tumours in mice, envisaging the creation of a rationale for more
effective bladder cancer therapeutics.
Materials and Methods
Ethics Statement
This work involves experiences in tumour samples of patients diagnosed with bladder cancer
in the Portuguese Insitute of Oncology of Porto. All procedures were performed after patient’s
written informed consent and approved by the Ethics Committee of Portuguese Institute of
Oncology—Porto. All clinicopathological information was obtained from patients’ clinical
records.
It also involves animal experiments. All procedures involving animals were performed in
accordance with the European Directive 2010/63/EU. During the course of this study, the ani-
mals were fed ad libitum with standardized food (Tecklad Global Diet, Harlan, Spain). The fol-
lowing protocol was approved by the Portuguese Ethics Committee for Animal
Experimentation (Direção Geral de Veterinária, Approval no. 520/000/000/2003). All mice
used in the experiment were acclimatized for one week under routine laboratory conditions
before starting the experiments. They were housed randomly in groups of 4–5 in plastic cages,
with hard wood chips for bedding. The animals were maintained in a room with a controlled
ribosomal protein S6 (pS6), and the eukaryotic translation initiation factor 4E–binding protein 1 (4E-BP1). For the protein mTOR to activate its signalling
cascade, it must form the rapamycin-sensitive ternary complex mTORC1. Key PI3K/Akt/mTOR-pathway proteins pAkt, pmTOR and pS6 explored in this
studied are highlighted by orange circles.
doi:10.1371/journal.pone.0141253.g001
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temperature of 23±2°C, a 12-hour light/dark cycle and 55±5% humidity. The animals' drinking
solutions were changed once a week or earlier if necessary, and the volume drunk was recorded.
Weekly food intake was also noted. All mice were monitored throughout the experiment for
signs of distress and loss of body weight. The animals were sacrificed with 0.4% sodium pento-
barbital (1 ml/Kg, intraperitoneal).
Population
This study was performed in a retrospective series of 96 formalin-fixed paraffin-embedded
bladder tumours obtained from archived paraffin blocks at the Portuguese Institute of Oncol-
ogy—Porto (IPOP), Portugal. Bladder tumours were extracted from 82 men and 14 women,
ranging in age from 38 to 92 years (median of 69.5 years), admitted and treated at the IPOP
between 2005 and 2007. Forty seven of the examined tumours were histologically classified as
NMBIC (Ta and T1) and 49 as invasive lesions (T2-T4). Sixteen were low grade and 80 were
high grade tumours, according to the 2004 WHO grading criteria. Furthermore, carcinoma in
situ (CIS) was found concomitantly in 20.8% of the patients. The average follow up time period
was 45 months (1–134 months). Cystectomy was performed in 64 patients (66.7%) while the
other 32 (33.3%) were submitted to transurethral resection. Lymphadenectomy was performed
in approximately 47% of the patients and from those 37% presented metastasis. Fifty four
(56.3%) tumours were primary and 42 (43.7%) were recurrent tumors. From the recurrent
tumours, 38% had no prior treatment, 27% were treated with Mitomicin C, 11% with BCG and
19% were submitted to both treatments. Moreover 5% of these patients were treated with
neoadjuvant chemotherapy prior to the cystectomy. Table 1 summarizes the clinicopathologi-
cal information.
Cancer-specific survival (CSS) was defined as the period between the tumour removal by
surgery and either patient death by cancer or the last follow-up information. All procedures
were performed after patient’s informed consent and approved by the Ethics Committee of
IPO-Porto. All clinicopathological information was obtained from patients’ clinical records.
Immunohistochemistry
The expressions of STn antigen, its precursor Tn, and phosphorylated forms of Akt (pAkt),
mTOR (pmTOR), S6 (pS6) and PTEN in bladder tumours were accessed by immunohis-
tochemistry using the avidin/streptavidin peroxidase method, as described by Ferreira et al.
[5]. Information on the primary antibodies and dilutions used in this study are summarized in
Table 2. Immunoreactivity was revealed using diaminobenzidine (DAB, Thermo Scientific
LabVision) as chromogen and sections were counterstained with Harris’s hematoxylin. Nega-
tive controls were performed by replacing the primary antibody with 5% bovine serum albu-
min (BSA). Positive controls were known positive tissues for the antigens under study.
Immunohistochemistry scoring of human tumours
The immunostained sections were assessed double-blindly by light microscopy by two inde-
pendent observers (CC and SP) and validated by an experienced pathologist (TA). Disaccord-
ing readings were re-analyzed using a double-headed microscope (Olympus BX46; Olympus
Corporation), and consensus was reached. A semi-quantitative approach was established to
score the immunohistochemical labeling based on the extent and intensity of the staining.
Given the absence of Tn and STn in the healthy urothelium [5], tumours were classified as
positive for these antigens when membrane and/or cytoplasmic immunoreactivity were
observed in more than 5% of the tumour, as described by Ferreira et al. [5,15]. pAkt, pmTOR,
pS6 and PTEN expressions were scored according to the staining intensity (weak-1 point;
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moderate-2 points; strong-3 points) multiplied by the percentage of positive cells (0–5%-0
points;>5–25%-1 point;>25–50%-2 points;>50–75%-3 points;>75–100%-4 points). Based
on the classification proposed by Nishikawa et al. [16], tumours with a score<6 were consid-
ered negative, whereas those with a score6 were classified as positive (overexpression). pAkt
was evaluated based on nuclear immunoreactivity, pmTOR and pS6 based on cytoplasmic
expression and PTEN on both cytoplasmic and nuclear staining, as suggested by other publica-
tions [17,18].
Animal experiments with sirolimus and immunohistochemistry scoring
Histological sections of Imprinting Control Region (ICR) mice bearing N-butyl-N-(4-hydroxy-
butyl) nitrosamine (BBN)-induced bladder lesions, resulting from our previous work on the
impact of sirolimus on bladder cancer [19], were elected for this study. Briefly, four-week-old
male ICR mice (25g; Harlan, Barcelona, Spain) were randomly distributed into four groups, as
described in detail in a previous publication [18]. Group 1 (n = 6) included mice exposed to
0.05% BBN for 12 weeks followed by tap water for 8 weeks (total of 20 weeks). Group 2 (n = 7)
included mice treated with 0.05% BBN solution for twelve weeks, maintained with normal tap
water for another week, administrated intraperitoneally with mTOR-inhibitor sirolimus (1.5
mg/kg; Wyeth) for five days a week for six consecutively weeks, i.e. until the 19th week, followed
by another week of tap water (total of 20 weeks). Group 3 (n = 6) included mice exposed to
0.05% BBN for 12 weeks followed by tap water for 11 weeks (total of 23 weeks). Group 4
Table 1. Clinical-pathological data of the studied sample (n = 96).
Age, years
median [min—max] 69.5 [38–92]
Gender, n (%)
Male 82 (85.4%)
Female 14 (14.6%)
Stage, n (%)
Ta 27 (28.1%)
T1 20 (20.8%)
T2 9 (9.4%)
T3 20 (20.8%)
T4 20 (20.8%)
Grade, n (%)
Low 16 (16.7%)
High 80 (83.3%)
Recurrence status, n(%)
Primary 54 (56.3%)
Recurrent 42 (43.7%)
Associated Cis, n(%)
No 76 (79.2%)
Yes 20 (20.8%)
Metastasis, n(%)
No 19 (63.3%)
Yes 11 (36.7%)
Follow-up, n (%)
Alive, lost or death from other causes 67 (69.8%)
Death from cancer 29 (30.2%)
doi:10.1371/journal.pone.0141253.t001
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(n = 7) included mice treated with 0.05% BBN and sirolimus, as described for Group 2, but
with an exposure to tap water afterwards of 3 weeks (total of 23 weeks). Group 3 and 4 were
created to estimate the possibility of late relapse and/or molecular alterations resulting from
prolonged survival. All procedures were performed in accordance with the European Directive
2010/63/EU. During the course of this study, the animals were fed ad libitum with standardized
food (Tecklad Global Diet, Harlan, Spain). The histological changes induced by these experi-
ments included both preneoplastic and neoplastic lesions with invasive potential and invasive
tumours, as described in detail by Oliveira et al. [18]. Herein, lesions of high invasive potential
and muscle invasive tumours were screened for STn and pS6 by immunohistochemistry, as
described in detail for human tumours, since the antibodies used are reactive against both
human and mice. Both the intensity and the extension of immunostaining were taken into con-
sideration to score the expression of the antigens, as described in the previous section. The
bladder lesions and immunostaining were assessed double-blindly by two independent observ-
ers (CC and SP) and validated by an experienced veterinary pathologist (RMGC).
Statistical analysis
Statistical data analysis was performed with IBM Statistical Package for Social Sciences—SPSS
for Windows (version 20.0). Chi-square analysis was used to compare categorical variables.
Kaplan-Meier survival curves were used to evaluate correlation between STn expression and
cancer-specific survival (CSS) and were compared using log-rank test. Furthermore, multivari-
ate Cox regression analysis was performed to assess the individual effect of the evaluated mark-
ers on patient’s survival and adjust to potential confounders (variables that could affect CSS of
NMIBC and MIBC patients). The correlation between PI3K/Akt/mTOR pathway molecules
was performed using Spearman rho test.
Results
Altered protein glycosylation, translated by the expression of the STn antigen and its precursor
Tn, PI3K/Akt/mTOR pathway molecules (pAkt, pmTOR, pS6), and PTEN inactivation, are
salient features of bladder tumours. Herein we have devoted to a comprehensive analysis of
these molecular alterations in a series of bladder cancer patients at different stages of the dis-
ease, envisaging biomarkers of poor cancer-specific survival.
Our dataset was composed by 47 NMIBC and 49 MIBC patients, as showed in Table 1.
According to Fig 2, NMIBC presented a higher cancer-specific survival (CSS; mean CSS: 119
months) than MIBC patients (mean CSS: 43 months; log rank, p<0.001). These results
Table 2. Antibodies used in the immunohistochemical analysis.
Antibody Vendor Clone Dilution
Tn Non-commercial Hybridoma* IE3 1:5
STn Non-commercial Hybridoma* TKH2 1:20
Ki-67 Dako MIB-1 1:100
p53 Dako DO-7 1:100
Phos-AKT Cell Signaling Ser473 (736E11) 1:50
Phos-mTOR Cell Signaling Ser2448(49F9) 1:100
Phos-S6 Cell Signaling Ser240/244 polyclonal 1:75
PTEN Cell Signaling D4.3 XP 1:50
*Kindly provided by Prof. Celso Reis (IPATIMUP, UP, Portugal)
doi:10.1371/journal.pone.0141253.t002
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demonstrated that our series reflected the natural course of disease and highlighted the signifi-
cantly lower CSS of MIBC compared to NMIBC cases. Therefore, particular interest was set in
the identification of biomarkers for late stage disease based on the comparison between
NMIBC and MIBC.
Tn and STn antigen expressions in bladder cancer
The Tn antigen was observed in approximately 10% of NMBC and MIBC (Table 2) and its
expression was residual, did not exceeding 5% of the tumour area and without any defined pat-
tern. On the other hand, the STn antigen was detected in approximately 60% of the studied
bladder tumours, which is in accordance with our previous findings [5]. The antigen was pre-
dominately expressed at the cell membrane, although cytoplasmic staining could also be
observed. The STn antigen presented a focal expression that did not exceed 30% of the tumour
area for the majority of the positive cases, irrespectively of their histological origin. STn was
mainly expressed by dedifferentiated cells in tumours showing lamina propria (T1; 60%) and
muscularis propria ( T2; approximately 60–90%) invasion; conversely the percentage of posi-
tive Ta was lower than 30% (p<0.001; Fig 3A). Although without statistical significance, in Ta
tumours STn positive cells were mainly present in superficial tumour layers away from the ves-
sels. Conversely, STn positive cells in T1 tumours (Fig 3B) were observed accompanying and/
Fig 2. Association between disease groups and cancer-specific survival (CSS) in the studied patients.
Kaplan-Meier analysis showing the CSS of NMIBC (Ta and T1) and s of MIBC (T2,T3 and T4). Comparison
performed by log-rank test (p<0.001); + censored NMIBC patients; ^ censored MIBC patients.
doi:10.1371/journal.pone.0141253.g002
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or invading the basal layer (Fig 3B), while in MIBC these cells were mostly found in the inva-
sion fronts (Fig 3B) and invading and/or inside the vessels, which suggests a role in invasion
and disease dissemination. Reinforcing these observations, the presence of STn antigen was sta-
tistically higher in MIBC when compared to NMIBC (p = 0.001, Table 3).
PI3K/Akt/mTOR pathway in bladder cancer
The evaluation of the PI3K/Akt/mTOR/S6 pathway was done using antibodies for active phos-
phorylated forms of Akt (pAkt), mTOR (pmTOR), and S6 (pS6). PTEN, that negatively regu-
lates Akt signalling, was also evaluated.
pAkt was detected both in the cytoplasm and nucleus. In NMIBC cases several areas with
different intensity of expression were observed (Fig 4A), denoting a heterogeneous pattern that
was not evident in MIBC (Fig 4B). Furthermore, stromal cells of MIBC positive cases showed
enhanced staining intensity mainly in the areas close to the tumour. pmTOR immunoreactivity
Fig 3. STn expression in different bladder tumors stages. (A) Distribution of STn negative and positive tumors along the different stages of bladder
cancer; (B) Representative images of STn staining in NMIBC and MIBC. Left—NMIBC showing a predominance of STn positive cells in the superficial layers,
away from the fibrovascular support; note vessels without positive cells. Right—MIBC showing the invasion front with STn positively stained cells; note
positive STn urothelial cells in the vessels (arrow), suggesting possible involvement in metastasis.
doi:10.1371/journal.pone.0141253.g003
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was cytoplasmic and, in occasional cases, nuclear. In urothelium with apparent normal histol-
ogy pmTOR expression was restricted to superficial cell layers. In NMIBC pmTOR expression
was evenly distributed across the several layers of urothelial cells, although there was a more
intense staining in the superficial layers (Fig 4C). Moreover, several areas with variable staining
intensity were observed, denoting a heterogeneous expression. In MIBC positives cases,
pmTOR expression was focal and heterogeneous (Fig 4D). pS6 immunoreactivity was predom-
inantly cytoplasmic. In NMIBC pS6 expression was noted in all the superficial layers, both in
umbrella and differentiated cells (Fig 4E). The immunoreactivity of pS6 varied across the
tumour cells. In MIBC pS6 presented a diffuse expression throughout the tumour, being more
present in basal and mitotic cells (Fig 4F). Several positive cases presented increased pS6 stain-
ing intensity in the invasion front as well as pS6 expression in tumour infiltrating lymphocytes
and endothelial cells.
Taking into account the extension of staining and its intensity, 62/94 (66%), 33/96 (34%)
and 45/95 (47%) of the bladder tumours were considered positive for pAkt, pmTOR and pS6,
respectively. A Spearman rho test showed that pAkt, pmTOR, pS6 expressions were signifi-
cantly correlated (P<0.05) irrespectively of the tumour stage, thus in accordance with a fully
active pathway. Furthermore, despite histological differences, these markers presented an equal
distribution among the NMIBC and MIBC and could not be associated with muscle invasion
(Table 3).
On the other hand, 37/92 (40%) of the tumours were considered positive for PTEN. PTEN
was expressed in the cytoplasm and nucleus of the same cells, however with lower extension of
expression in MIBC (33%, Fig 4G) compared to NMIBC (83%; Fig 4H). Moreover, the PTEN-
negative phenotype was significantly associated with muscle invasion (Ta and T1; p<0.001,
Table 3), which may contribute to maintain an active PI3K/Akt/mTOR/S6 pathway in these
cases.
Table 3. Association between the evaluatedmarkers and the stage of disease.
Bladder Cancer
NMIBC MIBC P
n (%) n (%)
Tn
Negative 41 (87.2) 45 (91.8)
Positive 6 (12.8) 4 (8.2) 0.461
STn
Negative 27 (57.4) 12 (24.5)
Positive 20 (42.6) 37 (75.5) 0.001
pAKT
Negative 13 (28.9) 19 (38.8)
Positive 32 (71.1) 30 (61.2) 0.312
pmTor
Negative 30 (63.8) 33 (67.3)
Positive 17 (36.2) 16 (32.7) 0.717
pS6
Negative 22 (47.8) 28 (57.1)
Positive 24 (52.2) 21 (42.9) 0.183
PTEN
Negative 18 (38.3) 37 (82.2)
Positive 29 (61.7) 8 (17.8) <0.001
doi:10.1371/journal.pone.0141253.t003
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Fig 4. Expressions of pAkt, pmTOR, pS6 and PTEN in NMIBC and MIBC (40xmagnification). A and B)
pAKT nuclear and cytoplasmatic expression in NMIBC (A) and MIBC (B). In NMIBC cases pAkt presented a
heterogeneous pattern with areas of different intensity of expression. In MIBC, stromal cells mainly in the
areas close to the tumour showed higher expression. C and D) pmTOR cytoplasmic expression in NMIBC (C)
and MIBC (D). In NMIBC pmTORwas expressed across several layers, although there was a more intense
staining in the superficial ones. In MIBC positive cases pmTOR expression was focal. E and F) pS6
cytoplasmatic expression in NMIBC (E) and MIBC (F). In NMIBC pS6 expression was observed in all the
superficial layers both in umbrella and differentiated cells. In MIBC the immunoreactivity was diffuse, however
more present in basal and mitotic cells. pS6 expression was higher in the invasion front and in tumour
infiltrating lymphocytes and endothelial cells. G and H) PTEN cytoplasmic and nuclear expressions in NMIBC
(G) and MIBC (H). PTEN expression was higher in NMIBC compared to MIBC.
doi:10.1371/journal.pone.0141253.g004
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Tn, STn, PI3K/Akt/mTOR pathway and Cancer-specific Survival
A Kaplan-Meier analysis was used to evaluate associations between the addressed biomarkers
and the cancer-specific survival of patients. We observed that patients bearing STn expressing
tumours had a lower CSS, irrespectively of their stage (p = 0.024; Fig 5A). This was also
observed when evaluating NMIBC alone (p = 0.020; Fig 5B). More importantly, among
NMIBC, STn expressing T1 tumours presented lower CSS than negative tumours (p<0.05).
Moreover, multivariate Cox regression analysis adjusted to potential confounders, namely age,
gender, stage, grade, recurrence status, presence of concomitant CIS was performed. We found
that STn is an independent prognostic marker of worst CSS (HR = 11.836; 95%CI: [1.063–
131.7]; p = 0.044). Contrasting with STn, positive Tn, pAkt, pmTOR and pS6 tumours showed
no differences in CSS compared to negative lesions, irrespectively of their stage. We have also
observed that patients harbouring PTEN-negative tumours had lower CSS (p = 0.015, Fig 6).
More studies are necessary to determine if the lack of suppressive effect of PTEN over PI3K/
Akt/mTOR may account for these findings.
Based on these observations and aiming to improve the prognostic value of STn in the con-
text of late stage disease (MIBC), we have comprehensively integrated the information from
STn and PI3K/Akt/mTOR pathway biomarkers. According to Fig 7, the introduction of PI3K/
Akt/mTOR pathway molecules allowed discriminating STn positive MIBC tumours with worst
CSS (p = 0.027). Furthermore, multivariate Cox regression analysis (adjusted to age, stage,
recurrence status, presence of concomitant CIS and metastasis) revealed that the presence of
PI3K/Akt/mTOR pathway molecules in STn+ MIBC is independently associated with approxi-
mately 6-fold risk of death by cancer (HR = 5.662; 95%CI: [1.093–29.323]; p = 0.039). These
observations suggest, for the first time, that the combination of STn and mTOR pathway bio-
markers may hold potential to improve the stratification of advanced stage bladder tumours;
however corroboration in larger series is mandatory.
Inhibition of the PI3K/Akt/mTOR pathway in animal models
BBN-induced mice bladder tumours mimicking the histology and molecular nature of human
cancers [20,21], were screened for STn and pS6, the downstream effector of mTOR pathway.
We observed no STn expression in the healthy mice urothelium, in accordance with previous
observation for the healthy human bladder [5]. In mice healthy urothelium pS6 expression was
below 20%, thus underexpressed when compared with BBN-exposed mice (Fig 8). In the con-
trol groups (Group 1 and 3, Fig 8A), the exposure to BBN led to the development of invasive
tumours in 70–90% of the studied mice. Concomitantly, 83–100% of the invasive lesions over-
expressed the STn antigen and all significantly overexpressed pS6 (Fig 8B). This demonstrated
that BBN-induced lesions were able to recapitulate the association between altered glycosyla-
tion and an activated PI3K/Akt/mTOR pathway previously observed in advanced stage human
tumours. The STn antigen was mainly found in cells adjacent to the basal layer and in those
invading the stroma, as previously observed in human tumours (Fig 8B and 8C). Conversely,
pS6 presented a more diffuse expression, again in accordance with the pattern observed in
human lesions (Fig 8B and 8C). A comparison between groups 1 and 3 further highlighted that
extended lifespan did not alter the number of invasive lesions, but significantly increased STn
and pS6 overall expressions in each tumour (p<0.05; Fig 8B), highlighting the more aggressive
nature of Group 3 lesions.
In the sirolimus-treated groups (Groups 2 and 4; Fig 8A) a smaller number of mice devel-
oped invasive tumors (20–40%) when compared to the controls (Groups 1 and 3). Moreover,
only 43% of the mice treated with sirolimus overexpressed the STn antigen, irrespectively of
the experience periods. Still, the extension of STn expression was significantly decreased in
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STn-positive tumours when compared to the control groups (Fig 8B and 8C). Following the
same tendency, the pS6 protein was only overexpressed in 29% of the cases in Group 2 and the
extension of expression was also significantly decreased (Fig 8B and 8C). Contrastingly, the
expression of pS6 in Group 4 was higher than in Group 2, again translating the higher aggres-
sive nature of tumours obtained after longer lifespan. Despite these observations, sirolimus
treatment promoted a significant reduction in the percentage of positive pS6 cells in Group 4
mice when compared to Group 3 (p<0.05; Fig 8B and 8C). Altogether, sirolimus administra-
tion effectively reduced tumour burden and promoted a significant reduction in the expression
of STn and pS6 markers.
Discussion
Due to their high molecular heterogeneity, advanced stage bladder tumours present a signifi-
cant prognostication and treatment hurdle. In this context, much controversy exists regarding
the potential of conventional cancer biomarkers, urging the identification of novel molecules
capable of aiding disease personalization. Furthermore, advanced stage bladder cancer remains
an orphan disease in terms of therapeutics, as the only available options continue to be surgery
and conventional chemotherapy [22]. The introduction of targeted therapeutics is therefore
warranted.
In a previous explorative study we have observed that altered protein glycosylation trans-
lated by STn overexpression was a salient feature of a subset of advanced stage tumours [5].
Herein we have started by investigating the expression of STn precursor, the Tn antigen, in
bladder tumours. We observed that this antigen presented a very low expression in bladder
Fig 5. Effect of STn expression in cancer-specific survival (CSS). Kaplan–Meier analysis showing the association between STn and CSS in: (A) all
studied bladder cancer patients; (B) NMIBC patients. Comparison performed by log-rank test (A: p = 0.024; B: p = 0.020); + censored STn negative tumours;
^ censored STn positive tumours.
doi:10.1371/journal.pone.0141253.g005
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tumours and was not associated with any particular stage of the disease. These findings suggest
that the Tn antigen is rapidly sialylated or capped with more extended glycans in bladder
tumours. Moreover, we have confirmed that STn expression is more associated with muscle
invasive than non-muscle invasive disease in a larger patient set, suggesting that sialylation
plays a key role in stopping protein glycosylation in advanced stage bladder tumours. Further-
more, we have provided new insights regarding its correlation with decreased survival, as previ-
ously observed for digestive track tumours [23–25]. Accordingly, we and other authors have
shown that STn expression is responsible by the modulation of cell surface glycoprotein func-
tions in ways that favour malignant phenotypes in gastric [26], breast [27] and bladder [5] can-
cers. Namely, STn expression altered the adhesive properties of cancer cells, possibly by
impairing integrin function [26,27]. Furthermore, it enhanced cell motility, invasion [26,27]
and epithelial-to-mesenchymal transition, a key event leading to metastasis [28]. We have also
demonstrated that STn expression protects bladder cancer cells from adverse host immune
responses [6]. Namely, it impaired dendritic cell maturation inducing a tolerogenic phenotype
and limiting their capacity to trigger protective anti-tumour T-cell responses [6]. In resume, a
significant amount of data supports a key role of STn in disease progression and dissemination,
making of STn antigen, and in particular STn-glycoproteins, potential anti-cancer targets. Nev-
ertheless, there is scarce information about the molecular nature of this subset of STn-express-
ing aggressive tumours and consequently about the best therapeutic options.
Fig 6. Effect of PTEN expression and cancer-specific survival (CSS) in the studied patients. Kaplan-
Meier analysis showing the effect in CSS of PTEN expression in all studied bladder cancer patients.
Comparison performed by log-rank test (p = 0.013); + censored PTEN negative tumours; ^ censored PTEN
positive tumours.
doi:10.1371/journal.pone.0141253.g006
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Foreseeing a more accurate patient stratification we have also addressed the expression of
PI3K/Akt/mTOR pathway markers in bladder tumours. In our series the activation of mTOR
pathway proteins did not discriminate the stage of disease. Moreover it did not allow, by itself,
the identification of patients facing worst prognosis, which is in accordance with recent publica-
tions [29,30]. However, we found that PTEN expression, which exerts a suppressive effect over
the PI3K/Akt/mTOR pathway, was decreased in advanced stage tumours, in accordance with
previous observations [31–34]. Furthermore, PTEN-negative MIBC presented worst cancer-spe-
cific survival in comparison to PTEN-positive lesions. More studies are needed to determine if
the lack of suppressive effect over the PI3K/Akt/mTORmay account for poorer outcome. Inter-
estingly, we have also observed that the overexpression of PI3K/Akt/mTOR pathway biomarkers
decisively associated with worst CSS in STn positive advanced stage tumours, which currently
lack effective therapeutics. These findings lead us to hypothesize that this subset of more aggres-
sive bladder tumours may benefit frommulti-targeted approaches combining mTOR-inhibitors
and guided therapeutics against STn-expressing cells. However these are preliminary insights
from a relatively low number of patients. More studies involving a large population are war-
ranted to confirm these observations. It will also be important to evaluate other outcomes of
aggressiveness, namely response to conventional therapeutics and metastasis development.
Our study also reinforced that bladder tumours present extensive activation of the PI3K/Akt/
mTOR pathway irrespectively of their histological nature, as described in previous publications
[32,35]. Such findings contribute to support the idea that most bladder tumours may be good
candidates for mTOR-inhibitors therapeutics. Accordingly, mTOR-inhibitors have been
Fig 7. Effect of PI3K/Akt/mTOR pathway activation in cancer-specific survival (CSS) of patients with
STn positive MIBC. Kaplan–Meier analysis showing the association between pAKT, pmTOR and pS6
expressions in the CSS of STn positive tumors MIBC: Comparison performed by log-rank test (p = 0.027);
+ censored pAKT and pmTOR and pS6 negative tumours; ^ censored pAKT and/or pmTOR and/or pS6
positive tumours.
doi:10.1371/journal.pone.0141253.g007
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extensively explored in pre-clinical settings and two phase I/II clinical trials for bladder cancer
are ongoing [36]. In particular our group has demonstrated that the combination of everolimus
with cisplatin or gemcitabine decreased the proliferation of bladder cancer cell lines in compari-
son to the chemotherapy agent alone [14,37]. More recently we conducted studies in mice bear-
ing chemically-induced tumours mimicking the histological and molecular nature of human
tumours [20]. We concluded that administration of mTOR-pathway inhibitor sirolimus (rapa-
mycin) effectively reduced the frequency of invasive lesions. Using the same animal model, we
have now confirmed the anti-cancer activity of sirolimus in the context of aggressive bladder
disease. Namely, we observed a significant reduction in tumour burden accompanied by a loss
of pS6 expression, thus in accordance with the expected mechanism of action of the drug. More-
over, we are describing for the first time that chemically-induced bladder tumours expressed the
Fig 8. STn and pS6 expressions in bladder tumours from BBN-exposedmale ICRmice with or without the administration of mTOR-inhibitor
sirolimus (rapamycin). A) Experimental design to determine the sirolimus effect on STn and pS6 expressions in a model of urothelial carcinogenesis (male
ICRmice). B) Expression of STn and pS6 in BBN-derived urothelial tumours in the presence and absence of sirolimus. BBN-induced bladder tumours
(Groups 1 and 3) overexpressed STn and pS6, which was more pronounced in Group 3, after longer lifespan. Exposure to sirolimus decreased the number of
invasive lesions in groups 2 and 4 (data not shown) and, concomitantly, decreased the expressions of STn and pS6. C) Histological sections showing the
expressions of STn and pS6 in BBN-induced urothelial tumours before and after treatment.
doi:10.1371/journal.pone.0141253.g008
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STn antigen, thereby mimicking the glycosylation pattern of human cancers. These observations
are of particular importance due the lack of accurate models to access the biological role of this
antigen. In fact most established cancer cell lines express residual amounts of this antigen,
denoting a dependence on the tumours microenvironment. We believe that BBN-induced
tumours may now constitute key models to develop successful therapeutics against STn positive
bladder lesions. Moreover importantly, we have concluded that the administration of sirolimus
contributed to reduce the number of STn positive cells. These observations reinforce a possible
association between STn and an active PI3K/Akt/mTOR pathway in invasive tumours, as sug-
gested upon the evaluation of human cancers. It also points out that sirolimus may constitute a
valuable approach to manage STn and PI3K/Akt/mTOR-positive, which face worst OS. Still,
these preliminary evidences and more in depth studies are needed before progressing to clinical
phases. Namely, it will be important to support these findings in other models such as patient-
derived xenografts and compare the effect of sirolimus with conventional chemotherapeutics
for bladder cancer (cisplatin/gemcitabine-based regimens).
In resume, we have demonstrated that the STn antigen is a biomarker of poor prognosis,
particularly in MIBC. We also suggest the existence of potentially more aggressive subgroup of
STn positive MIBC characterized by an active mTOR-pathway. Such observations also provide
the first link between these two apparently unrelated events in bladder cancer (altered glycosyl-
ation and the PI3K/Akt/mTOR-pathway activation). Using animal models we have also con-
cluded that the administration of mTOR-pathway inhibitor sirolimus offers potential against
these highly malignant tumours. More validation studies are now warranted to set the pace for
clinical trials. Taking into consideration its cell-surface nature and key role played by STn
malignancy, specific antibody-based therapeutics can also be envisaged [22,38]. The combina-
tion of these approaches may provide novel ways to improve MIBC management, which
remains an orphan disease in terms of innovative treatments [22].
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Bladder cancer can be classified into two groups: non muscle invasive (NMIBC - 
stages Ta, T1 and TIS) and muscle-invasive or metastatic bladder cancer 
(MIMBC; T2–T4). NMIBCs tend to recur but rarely progress to invasive cancer. On 
the other hand, MIMBCs have a high morbidity and mortality, in spite of the 
treatment. Clearly, objective biomarkers are needed in clinics to complement 
conventional clinicopathological markers to predict prognosis, treatment response 
and survival in both NMIBC and MIMBC patients. 
 
STn is known to influence cell recognition by the immune system [132], affect 
processes as cell cycle, apoptosis, and actin cytoskeleton dynamics, decrease 
cell-cell aggregation and increase extra-cellular adhesion, migration, invasion 
[39,133,134,135] and metastization [89]. Overexpression of STn antigen has been 
detected in several human carcinomas and preneoplastic lesions [77], whereas 
low or no expression was observed in the respective normal tissues [84]. 
Despite the cancer-associated nature of the STn antigen, few studies have been 
presented for bladder cancer. 
 
Within the line of this thesis, the first study (Paper I) aimed to understand the 
mechanisms underlying the presence of STn in bladder tumours.  In this study, 
with 69 patients (50 NMIBC and 19 MIBC) STn was not expressed in the healthy 
urothelium (6 samples); however, 46% of the bladder tumours presented cells with 
STn membrane and/or cytoplasmic staining, demonstrating the tumour-specific 
nature of this antigen. The results showed that STn expression was lower in low-
grade (LG) NMIBC (21% STn+ tumours) compared to high-grade lesions (HG; 
67% STn+ tumours), which include papillary tumours (76% STn+ tumours), CIS 
(20% of STn+ tumours), and MIBC (74% STn+ tumours). Altogether, these results 
highlight an association between the STn antigen and high grade NMIBC 
(p<0.002) as well as with muscle invasive tumours (p<0.03). 
Contrastingly, Langkilde (1992) reported no association between tumour 
progression to invasion and the expression of sialyl-Tn-antigen, which probably 
lead them to abandon this marker in bladder cancer [126]. However, in vitro 
studies have demonstrated that STn expression enhanced the invasion capability 
of bladder cancer cells [130]. Despite the controversy about the prognostic value 
of STn in bladder cancer, this marker was again target of research and, according 
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to the obtained results; it seems to be of promising biological value (Paper I). As 
so, STn may also be monitored noninvasively in urine or serum using the CA72-4 
test as is the case of other human carcinomas [28]. This could probably allow 
decreasing the number of cystectomies in post-surgery follow-up of patients with 
high-grade tumours, preventing major morbidities. 
 
It was known, from the previous study that STn was mainly expressed by HG 
papillary NMIBC, known for their elevated risk of recurrence and progression to 
muscle invasive disease and in MIBC that encompass an elevated risk of 
metastization and present decreased overall survival [22]. Further, that STn 
expression was also associated with elevated Ki-67, a proliferation-related 
molecule and a surrogate biomarker of increased risk to recurrence and 
progression in bladder tumours [136,137]. BCG is currently used for CIS and 
recurrent superficial disease of the bladder [15]. The response to intravesical 
treatment with BCG or chemotherapy is an important prognostic factor for 
subsequent progression and death caused by bladder cancer. Approximately 10-
20% of complete responders eventually progress to muscle-invasive disease, 
compared with 66% of non-responders [22]. There are evidences that STn 
expression may modulate the cell–BCG interaction [39,134,138] as well as 
immune responses [94,99,139] 
With the second paper (Paper II), it was hypothesize that STn might modulate 
BCG attachment to tumour cells and/or immune response and consequently 
influence BCG immunotherapy outcome. STn is a biomarker of concomitant 
molecular alterations that may further determine the tumour behaviour [140]. As 
such, in this study the role of STn was evaluated in the context of the response of 
bladder tumours to BCG immunotherapy, because nothing was known about the 
way patients exhibiting STn-positive tumours respond to treatment. 
The study was performed in a series of 94 (38 LG, and 56 HG) NMIBC that were 
treated with transurethral resection followed by for BCG intravesical 
immunotherapy. 
Approximately 66% of the studied bladder tumours were STn positive. Additionally, 
10 out of 32 STn negative cases were positive for S6T, which can be considered a 
form of the STn antigen masked by a Gal residue O-3 linked to the GalNAc 
moiety, and so, structurally related to STn. 
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The expression of STn alone or in combination with S6T (STn/S6T) was 
associated with high-grade tumours (p=0.007; p=0.037, respectively) and also with 
primary tumours (p=0.001; p=0.039, respectively). 
Of the 94 samples, 36 recurred after BCG treatment. The results showed that STn 
expression alone or in combination with that of S6T was associated with lower 
recurrence rates after BCG treatment. Furthermore, patients expressing STn 
and/or S6T presented longer recurrence free survival (RFS) and these antigens 
were found to be independent predictive markers of reduced recurrence after BCG 
immunotherapy. Moreover, recurrences after treatment displayed a reduced 
expression of STn antigens suggesting that BCG may be more effective against 
cells expressing these glycans. 
STn-expressing cells presented, in the study, enhanced capability for BCG 
adhesion and internalisation and higher BCG-mediated cell death in vitro. This 
strongly suggests that STn expression favours BCG-mediated elimination of 
tumour cells, which may, in part, explain the high correlation between these 
glycans and treatment response. Being STn a product of incomplete proteins O-
glycosylation, a reduction in the structural complexity of O-glycan may allow the 
bacillus to bind more efficiently to tumour cells [141].  
On the other hand, after Clement et al. (2004) describe that integrin b1 chains 
express STn and that the antigen enhanced integrin-fibronectin adhesion, and 
having present that BCG is known to bind fibronectin–a5b1 integrin complexes 
promoting a rearrangement of cytoskeletal actin in host cells [138], which results in 
the phagocytosis of the pathogen [142,143], it can be thought that this might be 
one reason STn may contribute to a more efficient binding of the bacillus to tumour 
cells and consequently a better response to BCG. 
By this time, it was a fact that STn was associated with invasion, better response 
with BCG immunotherapy, but still was missing the biological significance within 
MIBC - in Paper I only 19 MIBC were studied, while in Paper II no invasive 
tumours were contemplated.  
 
Paper III confirmed that STn expression is associated with muscle invasion in a 
larger patient set, and provided new insights regarding its correlation with 
decreased survival. In this study 96 cases were evaluated – 47 classified as 
NMIBC and 49 as MIBC; 16 as LG and 80 as HG. STn expression was statistically 
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associated with histological stage ≥T1-T4 (p<0.001), what corroborated Paper I. 
When cancer specific survival (CSS) was analysed, patients with STn positive 
tumours had a significant lower time of life from tumour treatment (p=0.024). In 
fact, it was even possible to observe the same when the NMIBC were taken alone 
(p=0.020), and also, when T1 tumours were evaluated. The T1 tumours 
expressing STn had a worse CSS when compared to the T1 STn negative ones 
(p<0.05). More, STn was found to be an independent prognostic marker of worst 
CSS (p<0.044), not yet stated in any other bladder cancer paper. These results 
strongly reinforce the first two studies, and now with a larger series, containing 
both NMIBC and MIBC in equivalent proportions.  
It has been demonstrated that STn expression is responsible for the modulation of 
cell surface glycoprotein functions in ways that favour malignant phenotypes, in 
different cancer models (gastric [39], breast [134]). Namely, STn expression 
altered the adhesive properties of cancer cells, likely by impairing integrin function, 
as said before [39,134]. Furthermore, it enhanced cell motility, invasion [39,134] 
and epithelial-to-mesenchymal transition, a key event leading to metastasis [144]. 
This knowledge is reinforced by the fact that in this third study, some MIBC STn 
positive cells were present in the front of invasion and, curiously (or not) vessels 
presented STn positive urothelial cells, while in STn positive NMIBC the 
immunostainnig was present away from the fibrovascular bundle, and no cells 
were observed inside the tissue vessels. 
Searching for a more accurate patient stratification, the expression of 
phosphatidylinositol-3-kinase (PI3K)/Akt / mammalian target of rapamycin (mTOR) 
pathway markers in the same series of bladder tumours was also addressed.  
The PI3K/Akt and the mTOR pathways are interconnected signaling cascades 
essential for bladder cell growth and survival. The PI3K/Akt/mTOR or mTOR 
pathway integrates signals initiated by nutrient intake, growth factors, and other 
cellular stimuli to regulate downstream signaling and protein synthesis, which 
ultimately leads to a competitive growth advantage, metastatic competence, 
angiogenesis, and therapy resistance [145]. 
In the studied series the results showed that the activation of mTOR pathway 
proteins did not discriminate the stage of disease. Moreover it did not allow the 
identification of patients facing worst prognosis, which is in accordance with 
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previous results regarding mTOR pathway evaluation in bladder tumours 
[146,147].  
Interestingly, advanced stage STn expressing tumours with an active 
PI3K/Akt/mTOR (positive pmTOR and/or pS6 - a downstream mTOR effector) 
showed a significantly worst CSS (p=0.027), allowing STn expression to 
discriminate between MIBC. More, those MIBC that presented STn positive 
expression concomitantly with the presence of PI3K/Akt/mTOR pathway 
molecules, had approximately, 6-fold risk of death by cancer (p=0.039).This was 
further reinforced when evaluating T2/T3 and T4 subgroups separately. Such 
observations strongly suggest that these particular tumours may be good 
candidates to mTOR-inhibitors therapeutics, such as sirolimus, an analog of 
rapamycin. This could be a way; however these are preliminary insights and need 
to be confirmed with a larger number of patients.  
Adding information to these studies, STn expression as well pS6, a downstream 
effector of mTOR, were also evaluated in a series of ICR mice that were submitted 
to N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) to develop bladder cancer [148]. 
For the first time, it is described that chemically-induced bladder tumours express 
the STn antigen, therefore also mimicking the glycosylation pattern of human 
tumours. This is of particular importance once it opens a door to animal models 
studies.  
The PI3K/Akt/mTOR pathway had been previously studied as well as the effect of 
sirolimus in the tumours of the same mice [148]. When STn and pS6 expression 
were evaluated, it was observed that those tumours that were treated with 
sirolimus had significantly lower expression in both molecules than the control 
groups. Despite the role played by STn in disease progression and its association 
with poor overall survival in humans, it can be infered that the administration of 
sirolimus was effective against STn positive cells. These observations also 
demonstrated, for the first time, an association between STn and an active 
PI3K/Akt/mTOR in invasive tumours. 
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Bladder cancer, a well studied tumour, still shows unpredictable outcomes 
irrespective the treatments. As so, is important to identify new biological 
markers or any biological mechanism that can discriminate more accurately 
bladder cancer outcome, adapting the treatments that will most benefit the 
patients.   
In this work, a more comprehensive description of STn antigen expression in 
bladder cancer expression was achieved. In spite of the knowledge and its 
prognostic value in other cancers, in bladder cancer concordant information had 
not been yet achieved.  
With the present work, it was clearly demonstrated that, STn was associated 
with advanced, highly proliferative tumours, invasion and organ disseminated 
disease, and with a significant decrease in cancer specific patient’s survival. All 
of these findings engender STn a prognostic marker of bladder cancer. 
Furthermore, STn antigen was found to be associated to high-grade NMIBC 
which currently constitutes one of the main therapeutics concerns due to their 
elevated risk of recurrence/progression. Adjuvant BCG immunotherapy has 
allowed to delay recurrence and decrease the risk of progression into muscle 
invasive disease, but still more than half of the patients either recur within two-
years after TUR or show intolerance to the treatment. Taking STn expression 
into account it was possible to create a predictive profile of treatment response. 
This posttranslational modification of proteins was found to influence both the 
adhesion to tumour cells and immune responses and may, therefore, directly 
interfere with BCG action. It has been demonstrated that STn antigen correlated 
with a better response to BCG treatment, strongly suggesting that BCG 
immunotherapy is efficient against STn-positive tumours. 
 
The present study also advocates the existence of potential more aggressive 
subgroup of STn positive MIBC characterized by an active mTOR-pathway, 
providing the first link between these two apparently unrelated events in bladder 
cancer (altered glycosylation and the PI3K/Akt/mTOR-pathway activation). More 
importantly, it sets the basis for novel therapeutic approaches against MIBC, 
like sirolimus, which may be translated for several other advanced stage solid 
tumours also known to overexpress the STn antigen. 
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Interestingly, it was observed that the STn antigen holds a dualism, in one hand 
is considered a poor prognosis factor, but on the other hand its presence 
benefits the treatment in patients with high grade NMIBC, but also MIBC 
patients. With all of the results, it is legitimated to think that vaccines towards 
STn, as well as the CA72-4 test to be used in serum or urine, are approaches 
that must be re-evaluated in the future.    
 
A final question can be raised: 
 
  - Once a patient develops a high grade bladder cancer, would it be preferable 
that was a STn positive one? 
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This study has provided important insights about STn prognostic value in clinical 
outcome of bladder cancer. Also new observations were found with respect to 
response to treatments. However, more studies are needed to truly disclose the 
role of the STn in the biology of urothelial bladder cancer. 
Significant results were achived concerning STn positive expression and its 
association with high grade and invasive bladder tumours, and also with the 
overall survival. In order to better understand and reinforce these results:   
 
- Enlarge the series is recommended, as the impact of the results will 
become more solid. Also ganglion metastization must be taking into 
account. 
- It will be important to go back to the first studied series (Paper I), inserted in 
a prospective study, and evaluate patients’ clinical outcome. It will be 
interesting to observe if there were recurrences and/or progression and if 
the positive STn primary tumours will be predictive of the different 
outcomes. 
- It will be of large interest to analyze serum and urine samples of patients 
with urothelial bladder tumours of all grades and stages, with the CA72-4 
test, as well as the tumours, with STn immunostaining, to understand if 
there is any relation that can be of clinical usefulness  
- Initiate a new series of animal studies, so the preliminary results can be 
consolidated, is an urgent question  
 
If the previous findings are corroborated, then a door can be open to more 
accurately treat bladder cancer patients, and vaccines against this glycosylated 
antigen can again be reconsidered. 
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